2019 ACR/ARP Abstract Disclosures
Study Sponsor Statements

0002: Baseline Cytotoxic Gene Expression Associates with Ustekinumab Response in Systemic Lupus Erythematosus

This study was sponsored by Janssen Research & Development, LLC

0004: AMP Deaminase 2 Surface Expression Counteracting CD73-Driven Generation of Anti-Inflammatory Extracellular Adenosine

This project is funded by an unrestricted grant by Horizon Pharma plc.

0011: Biomarker Changes for Patients with Rheumatoid Arthritis Receiving Tofacitinib with Methotrexate or Glucocorticoids vs Tofacitinib Monotherapy

This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Sarah Piggott, MChem, at CMC Connect, a division of McCann Health Medical Communications Ltd, Glasgow, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

0029: Therapeutic Anti-TNF Biologic Agents Exhibit Functional Differences in Blocking TNF-induced Effects on Human Monocytes In Vitro

AbbVie Inc. funded the study and was responsible for the study design, research, analysis, data collection, interpretation of data, and writing, reviewing and approving of the publication.

0031: Regulation of Neutrophil Extracellular Traps by Apremilast (phosphodiesterase 4 Inhibition)

Celgene provided funding for the research

0033: GS-4875, a First-in-Class TPL2 Inhibitor Suppresses MEK-ERK Inflammatory Signaling and Proinflammatory Cytokine Production in Primary Human Monocytes

This study was sponsored by Gilead Sciences, Inc.

0045: bDMARD-experienced Filgotinib-treated Patient Samples Exhibit a Partial Reversion to the Peripheral Molecular Profile of a Demographically Matched Healthy Population

The sponsor (Gilead Sciences, Inc.,) participated in the FINCH-2 trial design, and was responsible for coordinating the collection, management and analysis of the data. The academic authors and sponsor coauthors were responsible for drafting, editing, and revising of the abstract.

0046: Key Inflammatory Biomarkers at Baseline Are Associated with Filgotinib Response at Week 12 in Rheumatoid Arthritis Patients with Inadequate Response or Intolerance to Biologic DMARDs

The sponsor (Gilead Sciences, Inc.,) participated in the FINCH-2 trial design, and was responsible
for coordinating the collection, management and analysis of the data. The academic authors and sponsor coauthors were responsible for drafting, editing, and revising of the abstract.

**0049:** Towards a Single Cell Portrait of Rheumatoid Arthritis – Development of a Single Cell Multiomics Pipeline for Phase 2 of the Accelerating Medicine Partnership (AMP) – RA Network

This work was supported by the Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network. AMP is a public-private partnership (AbbVie Inc., Arthritis Foundation, Bristol-Myers Squibb Company, Lupus Foundation of America, Lupus Research Alliance, Merck Sharp & Dohme Corp., National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Pfizer Inc., Rheumatology Research Foundation, Sanofi and Takeda Pharmaceuticals International, Inc.) created to develop new ways of identifying and validating promising biological targets for diagnostics and drug development.

**0051:** Cigarette Smoking Has Different Impacts on ACPA and RF Production Depending on Shared Epitope Allele Status in Japanese RA Patients; A Study with the Two Independent Japanese Cohorts (IORRA and KURAMA)

KURAMA cohort study is supported by grant from Daiichi Sankyo Co. Ltd. This study is conducted as investigator initiate study. These companies had no role in the design of the study, the collection or analysis of the data, the writing of the manuscript or decision to submit the manuscript for the publication.

IORRA cohort study is supported by grant by twenty pharmaceutical companies (Daiichi Sankyo Co. Ltd., Mitsubishi-Tanabe, Chugai, Bristol-Myers Squibb, AYUMI, Astellas, Pfizer Japan Inc., Takeda Pharmaceutical, Eisai, Nippon Shinyaku, YL Biologics Ltd., AbbVie, Novartis Pharmaceutical K.K., Kaken Pharmaceutical Co., Ltd., UCB Japan, Ono Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Teijin Pharma, Torii Pharmaceutical Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd.). These sponsors were not involved in the: study design; collection, analysis, and interpretation of data; writing of the paper; and/or decision to submit for publication.

**0053:** Activation of the Desacetylase Sirtuin-1 Counteracts the Activated and Proangiogenic Profile of Endothelial Cells in Rheumatoid Arthritis and Alleviates Experimental Arthritis

This work was supported by a research grand from Pfizer (“Bourse Passerelle”). Pfizer was not involved in the study design, data acquisition, data analysis, or writing of this abstract

This work was also supported by the French Society of Rheumatology (SFR) and Arthritis R&D

**0054:** A Metagenome-wide Association Study of Gut Microbiome Revealed Novel Etiology of Rheumatoid Arthritis in the Japanese Population

**0059:** Evaluation of Potential Mechanisms Underlying the Safety Observations of Filgotinib in Clinical Studies in RA

This study was sponsored by Gilead Sciences, Inc.

**0065:** CD6 Modulation Ameliorates Skin and Kidney Disease in a Spontaneous Murine Model of SLE
This study was funded by Equillium, Inc who provided funds for work for hire and helped with the scientific design of the study.

**0066:** Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation
The study was sponsored by Equillium, Inc. The research was done as work for hire with funding provided for the study, as well as scientific input on the study design.

**0080:** The Role of Adopter Protein SH3BP2 in a Murine Systemic Lupus Erythematosus Model

**0084:** Cenerimod, a Potent and Selective Sphingosine-1-Phosphate Receptor 1 Modulator, Controls Systemic Autoimmunity and Organ Pathology in Mouse Models of Systemic Lupus Erythematosus and Sjögren’s Syndrome
This research was funded by Idorsia Pharmaceuticals Ltd. All authors are employees of Idorsia Pharmaceuticals Ltd.

**0085:** Selective Inhibition of the Immunoproteasome with KZR-616 Blocks Multiple Cell Signaling Pathways, Plasma Cell Signatures and Myeloid Cell Associated Damage in the NZB/W Lupus Nephritis Model
The study was funded and performed at Kezar Life Sciences.

**0098:** Selective Induction of Functional Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases
The study was funded by Nektar Therapeutics and Eli Lilly and Company, a co-development partner for NKTR-358. Nektar Therapeutics, as the sponsor, was responsible for designing, conducting and analyzing the study results.

**0107:** Expanded Peripheral T Helper Cells Characterize the Early Rheumatoid Arthritis Synovium
This study was funded by a research collaboration grant from Janssen Research & Development, LLC.

**0113:** In Vitro Characterization of the Effect of Cenerimod, a Potent and Selective Sphingosine 1-Phosphate Receptor 1 (S1P₁) Modulator, on S1P₁ Receptor Expression, Receptor Internalization, and Migration of Primary Human T Cells in the Presence or Absence of Glucocorticoids
This research was fully funded by Idorsia Pharmaceuticals Ltd. All authors are employees of Idorsia Pharmaceuticals Ltd.

**0120:** Administration of a CD45 Antibody Drug Conjugate as a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease
Magenta Therapeutics is a publicly traded company. The studies reported here were funded in full by Magenta Therapeutics. The authors listed receive income from and hold equity in Magenta Therapeutics.

**0121:** In Vitro Human Enthesitis Model with Induced IL-17A and TNFα from CD4+ and CD8+ T Cells and Effect of Pharmacological Antagonism with Janus Kinase and Retinoic Acid Receptor-related Orphan Receptor γ Inhibition
PhD project funded by Novartis

**0123:** Blockade of Antigen-specific T Cell Activation by a Non-Depleting Anti-HLA-DR Monoclonal Antibody with a Unique Binding Epitope
This study is fully funded by Janssen R&D and all authors in this study are full-time employee of Janssen R&D.

**0124**: Treatment with Abatacept but Not with TNF Blockers, Is Associated with a Reduction of Constitutively Elevated Circulating Follicular Helper T Cells in Rheumatoid Arthritis
*Nonrestricted Research grant by BMS*

**0181**: Prevalence of Renal Impairment in a US Rheumatoid Arthritis Population
*The study was sponsored by Eli Lilly and Company. The study sponsor designed the study, assisted with interpretation of the data and drafting the abstract.*

**0183**: Exploring Heterogeneity in Rheumatoid Arthritis: Patient Profiling Through Principal Component and Cluster Analysis of the BRASS Registry
*The BRASS registry is supported by Sanofi, Regeneron Pharmaceuticals, Inc., Bristol-Myers Squibb, and Crescendo Bioscience. Analyses presented here and medical writing support (Matt Lewis, Adelphi Communications Ltd) were funded by Sanofi and Regeneron Pharmaceuticals, Inc. This abstract was previously presented at the 2019 European Congress of Rheumatology; 12–15 June; Madrid, Spain.*

**0184**: No Increased Risk of Incidence Diabetes in Patients with Rheumatoid Arthritis Compared to Patients Without RA
*This study was supported by an investigator-sponsored research grant from Bristol-Myers Squibb. However, the study was conducted by the authors independent of the sponsor. The sponsor was given the opportunity to make non-binding comments on a draft of the manuscript, but the authors retained the right of publication and to determine the final wording.*

**0188**: The Importance of Diagnosis: Clinical Distinctions Between Adult JIA and RA, and a Characterization of Patients with JIA Reclassified as RA in Adulthood
*This study was funded by Bristol-Myers Squibb.*

**0189**: Validation of Claims-based Algorithms to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis
*This study was funded by Bristol Myers Squibb Pharmaceutical.*

**0194**: Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab Monotherapy Using Corrona Real World Data
*Genentech participated in this research as collaborators. Two authors are employees of Genentech. They gave input on the study protocol, results, and abstract.*

**0197**: The Relationship Between Pain and Patient Demographics, Clinical Features, and Health Outcomes in a Cohort of Rheumatoid Arthritis Patients Recruited and Studied Using a Mobile Application
*This work was fully sponsored by GSK. All authors are employees of GSK, and own GSK shares.*

**0204**: Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US
*Gilead Sciences, Inc. financially supported the study and participated in the planning, execution, and interpretation of the research.*
**0205**: Does a Mandatory Non-medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register-based Study of 1620 Patients with Inflammatory Arthritis

*The study was partly funded by Pfizer, who had no access to raw data and had no influence on the preparation of this manuscript or on the decision to publish these data.*

**0206**: Efficacy of Etanercept on Radiographic Progression in Adult Patients with Rheumatoid Arthritis or Psoriatic Arthritis: Final Results from a German Non-Interventional, Prospective, Multi-Center Study

*This study was funded by Pfizer Pharma GmbH.*

**0244**: Real-World Evidence Associated with the Treatment of Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review

*Janssen Scientific Affairs, LLC supported this study.*

**0245**: Comorbidities, Health Care Utilization, and Cost of Care in Systemic Lupus Erythematosus Increase with Disease Severity During 1 Year Before and After Diagnosis: A Real-World Cohort Study in the United States, 2004–2015

*AstraZeneca funded this study with employees providing input into the design, implementation, and analysis of the results of the study.*

**0248**: Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) — a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel

*Researchers work for Accredo, an Express Scripts Specialty Pharmacy, a Cigna subsidiary*

**0249**: Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity

*This study was sponsored by Bristol-Myers Squibb.*

**0250**: Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US

*Gilead Sciences, Inc. financially supported the study and participated in the planning, execution, and interpretation of the research.*

**0251**: Long-term Financial Impact of Switching from Reference to Biosimilar Etanercept When Considering Short-term Formulary Management Costs in the US

*This study was designed and conducted by Xcenda, in collaboration with the Sponsor, Sandoz Inc.*

**0254**: Interstitial Lung Disease Associated Health Care Resource Utilization and Cost in Rheumatoid Arthritis Patients in an Insured Population

*The study is conducted by the employees of BMS*

**0259**: Describing Treatment Patterns and Healthcare Costs in Newly Diagnosed Psoriatic Arthritis Patients by Physician Specialty

*This study was sponsored by Amgen, Inc.*

**0263**: Health Professionals Agreed with Recommendations to Evaluate and Optimize Adherence to Disease-modifying Treatments, but Perceived Feasibility Was Lower: A Study of 357 Physicians and Health Professionals in France
This project was conducted thanks to an unrestricted grant from Abbvie France (Rencontres d’Experts en Rhumatologie program). AbbVie employees were present during the Rencontres d’Experts en Rhumatologie meetings, but did not influence the scientific discussions. AbbVie did not review the content or have influence on this manuscript.

0267: Develop Risk Prediction Model and Drug Withdrawal Road Map Through Pattern Extraction and Data Mining: Create a Master Algorithm from the Smart System of Disease Management (SSDM)

Funding was received from Horizon Pharma. The sponsor had no role in the design, conduct or reporting of the study.

0340: Increased Physical Activity in Gout Patients Correlates with Better Prognosis, Decreased Pain, and Suppressed C-Reactive Protein Levels

Both Nicholas Young and Naomi Schlesinger had research support for this study via a grant from Ironwood Pharmaceuticals to examine the role of exercise in inflammation, which directly supported these research endeavors. Ironwood was not involved in designing, taking part, or writing the abstract.

0341: Development of a Multivariable Improvement Measure for Gout

This work was supported by Horizon.

0342: Rheumatologist Care Is Associated with Fewer Emergency Room Visits by Persons with Gout

This work was supported by Horizon.

0358: Emergency Department Encounters in a Large US Payer Database: Tophaceous versus Non-tophaceous Gout Patients

Authors of this abstract are employees of Horizon Therapeutics plc.

0369: Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review

0374: The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases

The INBUILD trial is funded by Boehringer Ingelheim
0390: Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Eli Lilly and Company provided drug and some support through a cooperative research and development agreement.

0417: Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis
The study was sponsored by Eli Lilly and Company, under license from Incyte Corporation. The study sponsor designed the study and provided data analysis, laboratory and site-monitoring services, and writing support.

0419: Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study
This study was funded by MSD, Greece

0420: Assessment of Fatigue in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Qualitative Study to Explore What Patients Feel Should Be Measured in Clinical Trials
Role of the Study Sponsor- TO BE ADDED

0421: An Examination of Patient-Reported Outcomes Data from a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Amgen Inc., the sponsor of this trial, designed the trial in collaboration with academic investigators, oversaw data collection, performed the data analyses, and supported the development of this abstract. Data interpretation and writing of the abstract were performed by both the Amgen and non-Amgen authors.

0422: The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis
AbbVie funded the study, contributed to the design, collection, analysis, and interpretation of the data, and in the writing, review, and approval of the abstract. Medical writing support was provided by Maria Hovenden, PhD, and Janet Matsuura, PhD, of Complete Publication Solutions, LLC (North Wales, PA) and was funded by AbbVie.

0423: Patient Reported Outcomes over 2 Years in Psoriatic Arthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Routine Care – Was PRO Remission Achieved? Results from the EuroSpA Collaboration
The EuroSpA Research Collaboration Network is financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, abstract preparation or decision to submit

0425: Differences in Correlation Between Objective Disease Measurements and Patient’s/physician’s Global Assessment in the Large Non-interventional Study SUSTAIN
This non-interventional study is initiated and funded by Janssen-Cilag.

0426: Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo
This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Eric Comeau, PhD at
CMC Connect, a division of McCann Health Medical Communications Inc, Radnor, PA, USA, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

0431: Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS®) Item Banks in a Dutch Clinical Sample of Children with Juvenile Idiopathic Arthritis This study was performed with an unrestricted grant number WP 465569 from Pfizer pharmaceuticals. Pfizer only provided funding and had no further role in the study.

0434: Ixekizumab Significantly Improves Patient-reported Overall Health as Measured by SF-36 in Patients with Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Trials Eli Lilly and Company funded this study. Lilly participated in the study design, data collection, and the analysis and reporting of study results.

0435: Understanding Which Patient-Reported Outcomes Are Important to Rheumatology Patients: Findings from ArthritisPower The study was sponsored by Eli Lilly and Company. The study sponsor participated in the design of the study, data interpretation and abstract writing.

0439: Improved Patient-Reported Outcomes in Patients with Persistently Active Rheumatoid Arthritis Following Treatment with Repository Corticotropin Injection Mallinckrodt Pharmaceuticals, ARD, LLC funded the study. Editorial support provided by MedLogix, Communications, LLC.

0444: Criterion Validity of the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) Questionnaire and FLARE-RA Cut-offs for Clinical Decision Making: International Collaboration - United States: Pfizer (Grant ID 15322005) - France: AbbVie (ACA-FRAN-11-02) - Denmark: Central Region Denmark Health Research Foundation, the Danish Rheumatism Foundation (grant A2920), the Novo Nordisk Research Foundation (grant NNF14OC0013029), and the Hede Nielsen Family Foundation - Argentina: None Funders had no role in study conduct or interpretation of the results.

0451: Persistent and Non-Articular Regional and Widespread Pain Are Common in Early Rheumatoid Arthritis, Impacting Remission Rates and Reflected in Patient Global Scores The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017 and Sandoz Canada, Biopharmaceuticals since 2019. Previously funded by Hoffmann-LaRoche and Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017.

0455: Anti-Protein-Arginine Deiminase (PAD) 4 IgA Are Present in the Sera of Rheumatoid Arthritis Patients and Are Associated with Joint Erosion and Biological Treatment Use Two of the authors that contributed to the study design, and performed the testing and data analysis are employees of Inova Diagnostics, an
In Vitro Diagnostics Company. The testing was done using non-commercially available tests for the novel biomarkers (research use only). One of the two employees is a PhD student and this work was performed as part of her thesis work.

0456: Vitamin D Is Not Associated with Treatment Responses in Patients with Newly Diagnosed Rheumatoid Arthritis
This study was funded by Eisai Korea. This funding source had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results.

0461: Maximal Improvement in Fatigue Lags Behind Achievement of Sustained Remission in Early Rheumatoid Arthritis
The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016 and Merck Canada since 2017. Previously funded by Hoffmann-LaRoche and Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017.

0465: Prognostic Factors and Clinical Outcome Modifiers in Patients with Rheumatoid Arthritis: A Review
This review was funded by Bristol-Myers Squibb. Doctor Evidence was contracted by Bristol-Myers Squibb to conduct this review.

0466: Predicting Risk of Radiographic Progression for Patients with Rheumatoid Arthritis
The study sponsor was involved in study design, data analysis, and data interpretation as encompassed by the author responsibilities of the authors from Crescendo Bioscience, Inc. and Myriad Genetics, Inc.

0470: Obesity Is a Robust Predictor of Persistent High Fatigue at 1 Year in Women and Men with Early Rheumatoid Arthritis
CATCH was designed and implemented by the investigators and supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie since 2011; Medexus since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017 and Sandoz since 2019. Previously funded by Hoffmann-LaRoche and Janssen from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017.

0471: When Will I Get past This Exhaustion? Predictors of Improved Fatigue in the First Year of RA
CATCH was designed and implemented by the investigators and supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie since 2011; Medexus since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017 and Sandoz since 2019. Previously funded by Hoffmann-LaRoche and Janssen from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017.

0482: Antibody Repertoire Sequencing, Antigen Array Analysis, and Cytokine Profiling of Blood from Individuals at High-risk for RA Reveals Candidate Immunoglobulin V Genes, ACPA, and Cytokines That May Promote the Transition to Arthritis
Funding for this study was provided by Janssen.

0488: Citrullinated Antigens with Multiple Citruline Similar Motif Could Be Used for RA Diagnosis
Samples were collected from hospital with clinical diagnosis result. The experiments were executed by the scientists of Leide Bioscience Inc.

0491: Diagnostic Performance of Anti-cyclic Citrullinated Peptide (CCP) 2 and CCP3.1 Assays in Early Rheumatoid Arthritis
Sascha Swiniarski and Christian Konrad are employees of Thermo Fisher Scientific. Based on a collaboration agreement between Thermo Fisher Scientific and Medizinische Universität Wien, Thermo Fisher Scientific provided the immunoassay kits for this study. The composition of the patient cohort and the analysis of the results were done by Daniela Sieghart and Günter Steiner and are their sole responsibility.

0494: Clinical and Biomarker Factor Associations with Symptoms and Future Development of RA: TIP-RA Collective
This project was funded by an investigator-initiated grant from Janssen Research and Development, LLC

0498: Should There Be Hierarchical Scoring Applied to Serologic Testing in the 2010 ACR/EULAR Classification Criteria?
Barbara Mascialino is employed by Thermo Fisher Scientific, manufacturer of CCP and RF tests. However, being based on the results of a Systematic Literature Review and Meta-Analysis, the results summarized in this abstract have general validity for any CCP and RF tests available on the market.

0499: The Generation of Anti-CCP Tests Affects Diagnostic Accuracy in Rheumatoid Arthritis: A Systematic Literature Review and Meta-Analysis
Barbara Mascialino, Linda Mathsson Alm, and Maryam Poorafshar are employees of Thermo Fisher Scientific.

0503: A Pilot Phase 1, Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P17 and Humira in Healthy Male Subjects
This study was sponsored by Celltrion, Inc.

0504: A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis
The study was funded by Galapagos NV and Gilead Sciences, Inc. The sponsors participated in the planning, execution, and interpretation of the research.

0506: Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results
This study was sponsored by Gilead Sciences, Inc.

0507: Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan
This study was initiated and sponsored by Astellas Pharma, Inc. Astellas was involved in the study design, data analysis, decision to publish, and preparation of the abstract.

0508: Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis
After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan

This study was initiated and sponsored by Astellas Pharma, Inc. Astellas was involved in the study design, data analysis, decision to publish, and preparation of the abstract.

0509: Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program

AbbVie, Inc was the study sponsor, contributed to study design, data collection, analysis, interpretation, writing, reviewing, and approval of the final version of the abstract.

0510: Treatment with Upadacitinib Is Associated with Improvements in Reverse Cholesterol Transport in Patients with Rheumatoid Arthritis: Correlation with Changes in Inflammation and HDL Levels

AbbVie, Inc was the study sponsor, contributed to the study design, data collection, analysis & interpretation, and to writing, reviewing, and approval of the final version.

0511: A Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials

AbbVie, Inc was the study sponsor, contributed to the study design, data collection, analysis & interpretation, and to writing, reviewing, and approval of the final version.

0512: Efficacy and Safety of Upadacitinib Monotherapy in MTX-naïve Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY

AbbVie, Inc was the study sponsor, contributed to study design, data collection, analysis & interpretation, and to writing, reviewing, and approval of final version.

0513: Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks

AbbVie, Inc was the study sponsor, contributed to study design, data collection, analysis & interpretation, and to writing, reviewing, and approval of final version.

0514: A Pooled Analysis of 1-year Clinical Outcomes Among 6-month Responders and Non-responders from Three Randomized Controlled Studies of TNF Inhibitor Biosimilars in Patients with Rheumatoid Arthritis

This study was sponsored by Samsung Bioepis Co., Ltd.

0515: Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib

AbbVie, Inc was the study sponsor, contributed to study design, data collection, analysis & interpretation.

0516: Impact of Baseline Demographics and Disease Activity on Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib

AbbVie Inc. was the study sponsor, contributed to the study design, data collection, analysis and interpretation, and to writing, review, and approval of the final version. Medical writing support was funded by AbbVie and provided by John Ewbank, PhD, of 2 the Nth.

0517: A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs

The study was funded by Galapagos NV and Gilead Sciences, Inc. The sponsors participated...
in the planning, execution, and interpretation of the research.

0518: Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks
AbbVie, Inc was the study sponsor, contributed to study design, data collection, analysis & interpretation, and to writing, reviewing, and approval of final version.

0519: Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components
Funding for this study was provided by Amgen, Inc.

0520: Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA
This study was funded by Amgen, Inc.

0522: Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis
AbbVie, Inc was the study sponsor, contributed to the study design, data collection, analysis & interpretation, and to writing, reviewing, and approval of the final version.

0523: The Impact of Upadacitinib versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis
AbbVie Inc. was the study sponsor, contributed to the study design, data collection, analysis and interpretation, and to writing, review, and approval of the final version. Medical writing support was funded by AbbVie and provided by John Ewbank, PhD, of 2 the Nth.

0524: A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies
AbbVie, Inc was the study sponsor, contributed to the study design, data collection, analysis & interpretation, and to writing, reviewing, and approval of the final version.

0527: Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks
AbbVie, Inc was the study sponsor, contributed to study design, data collection, analysis & interpretation.

0528: Assessment of Bone and Cartilage Turnover Markers Following Treatment with Repository Corticotropin Injection in Patients with Persistently Active Rheumatoid Arthritis
Mallinckrodt Pharmaceuticals, ARD, LLC funded the study. Editorial support provided by MedLogix, Communications, LLC.

0529: Characterization of Remission in Patients with Rheumatoid Arthritis Treated with Upadacitinib or Comparators
AbbVie, Inc was the study sponsor, contributed to study design, data collection, analysis & interpretation.

0530: Phase I Evaluation of the PDE4 Inhibitor LY2775240: Head to Head Comparison with Apremilast Using an Ex Vivo Pharmacodynamic Assay
Eli Lilly and Company sponsored and conducted this Phase 1 clinical study.

0532: A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients
with Rheumatoid Arthritis Inadequately Responding to Biologics

0533: Impact of Formulary Change on TNFi Treatment Patterns and Healthcare Utilization Costs in RA Patients
Amgen Inc. (Thousand Oaks, CA, USA) sponsored this study/analysis and was involved in the design and conduct of the study; management, analysis, and interpretation of the data; and preparation, review, and approval of the abstract.

0535: Exploratory Analysis of a Phase 2b Study Confirms Substantial Pain Improvement with Anti-GM-CSF Monoclonal Antibody Otilimab (GSK3196165) in Patients (Pts) with Active RA
Study funded by GSK (NCT02504671); GSK involved in design and data analysis. Medical writing support was provided by Olga Conn, PhD, Fishawack Indicia Ltd, UK (funded by GSK).

0536: PERFUSE: A French Prospective/Retrospective Non-interventional Cohort Study of Infliximab-naïve and Transitioned Patients Receiving Infliximab Biosimilar SB2; An Interim Analysis
Biogen International GmbH sponsored this study. Biogen provided funding for study design development, data collection and analysis of the data. Biogen reviewed and provided feedback on the abstract. Authors had full editorial control and provided final approval of all content.

0537: Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA
This study was sponsored by Amgen Inc.

0538: Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks
AbbVie, Inc was the study sponsor, contributed to study design, data collection, analysis & interpretation, and to writing, reviewing, and approval of final version.

0539: A Randomized Double-Blind Study Comparing Pharmacokinetics (PK) and Pharmacodynamics (PD) of ABP 798 with Rituximab in Subjects with Moderate to Severe RA
The study was sponsored by Amgen Inc.

0540: Comparing Real-world Retention Rates in a Matched Cohort of Rheumatoid Arthritis Patients Who Either Remained on the Etanercept Originator or Switched to a Biosimilar
RABBIT is supported by a joint, unconditional grant from AbbVie, Amgen, Bristol-Myers Squibb, Celltrion, Hexal, Lilly, MSD Sharp & Dohme, Mylan, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis und UCB.

0541: Multicenter, Evaluator-blinded, Randomized, Non-inferiority Study, to Assess the Efficacy, Safety and Immunogenicity of Etanercept Biosimilar (EtaBS) vs. Reference Etanercept (EtaRef) in Combination with Methotrexate for the Treatment of Patients with Rheumatoid Arthritis
The study sponsor has supported economically the study and was in charge of submitting the trial results to regulatory authorities. But it was not in charge of reporting the trial results to ACR

0542: ‘BENEFIT’ Pan-European Observational Study to Evaluate the Real-world Effectiveness
of SB4 Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis or Axial Spondyloarthritis: A Switch Success Story
Biogen International GmbH sponsored this study. Biogen provided funding for study design development, data collection and analysis of the data. Biogen reviewed and provided feedback on the abstract. Authors had full editorial control and provided final approval of all content.

0545: Molecular Analysis of the Mode of Action of Upadacitinib in Rheumatoid Arthritis Patients: Whole Blood RNA Expression Data from the SELECT-NEXT Study
AbbVie, Inc was the study sponsor, contributed to the study design, data collection, analysis & interpretation, and to writing, reviewing, and approval of the final version.

0546: Change in Rheumatoid Arthritis (RA)-Related Autoantibody Profile and Risk of Disease Flare After Withdrawal of Therapy in Patients with Early RA Treated with Abatacept and MTX
Bristol-Myers Squibb was involved in the design, conduct, analysis and reporting of the study. Professional medical writing: Catriona McKay, Caudex; funding: Bristol-Myers Squibb.

0547: Inhibition of Structural Joint Damage with Upadacitinib as Monotherapy or in Combination with Methotrexate in Patients with Rheumatoid Arthritis
AbbVie, Inc was the study sponsor, contributed to study design, data collection, analysis, interpretation, writing, reviewing, and approval of the final version of the abstract.

0548: Efficacy and Safety of a Novel Subcutaneous Formulation of CT-P13 over the 1-year Treatment Period and After Switching from Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis: Results from Part 2 of Phase I/III Randomized Controlled Trial
This study is sponsored by CELLTRION, Inc.

0549: US Rheumatologists’ Beliefs and Knowledge About Biosimilars – an Ongoing Survey
This survey was supported by Boehringer Ingelheim and was fielded in partnership with WebMD, LLC. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE), were fully responsible for all content and editorial decisions, were involved at all stages of abstract development, and have approved the final version of the abstract that reflects the authors’ interpretation and conclusions. The authors received no direct compensation related to the development of the abstract. Medical writing assistance, supported financially by Boehringer Ingelheim Pharmaceuticals, Inc. was provided by Marissa Buttaro, MPH, and Linda Merkel, PhD of Elevate Scientific Solutions, which was contracted and compensated by Boehringer Ingelheim Pharmaceuticals, Inc. for these services. Boehringer Ingelheim was given the opportunity to review the abstract for medical and scientific accuracy as well as intellectual property considerations.

0550: Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study
The study was funded by Galapagos NV and Gilead Sciences, Inc. The sponsors participated in the planning, execution, and interpretation of the research.
0551: Upadacitinib Treatment and the Routine Assessment of Patient Index Data 3 (RAPID3) Among Patients with Rheumatoid Arthritis

AbbVie Inc. was the study sponsor, contributed to the study design, data collection, analysis and interpretation, and to writing, review, and approval of the final version. Medical writing support was funded by AbbVie and provided by John Ewbank, PhD, of 2 the Nth.

0552: In the Real World Clinical Setting

Etanercept Biosimilar SB4(BENEPAIL®) Demonstrates Equivalent Safety and Effectiveness in Biological Naïve as Well as with ENBREL® Pretreated RA,SPA, and PSA Patients

unrestricted grant from Biogen

0553: Etanercept Biosimilar GP 2015 (Erelzi®) in Rheumatic Diseases: Interim Analysis of Real-World Data from COMPACT: A Multicentric, Prospective, Observational Cohort Study

0557: Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey

This study was funded by Eli Lilly and Company

0562: Development of a Set of ASAS Quality Standards for Adults with Axial Spondyloarthritis

ASAS funded this research. The Investigators retained full control of scientific and analytic content, and had final editorial responsibility.

0565: Evidence-Based Recommendations for the Management of Enteropathic Arthritis: A Rheumatology – Gastroenterology Collaborative Initiative

This work was supported by UCB Pharma through an unrestricted grant.

0567: Worse Outcomes for Female Patients with Axial Spondyloarthopathy

ASRI is supported by unrestricted funding from AbbVie and Pfizer

0570: Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up of Ankylosing Spondylitis (AS) Patients with a Rheumatologist-patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China

The Smart System of Disease Management is developed by Shanghai Gothic Internet Tehnology Co., Ltd

0572: Early Recognition of Patients with Axial Spondyloarthritis by Using a Practical Referral System – Evaluation of the Recently Proposed 2-step Strategy

This work was supported by an unrestricted Grant by Novartis Pharma GmbH, Germany. The Investigators retained full control of scientific and analytic content, and had final editorial responsibility

0577: Gender Contrasts in Patient Reported Outcomes Don’t Alter the Disease Activity Score in Axial Spondyloarthritis Patients

The Be-Giant consortium is supported by AbbVie

0583: A Biomarker of Type VI Collagen Degradation (C6M) Is Associated with Changes in ASDAS MRI Measures of Inflammation in Patients with Axial Spondyloarthritis During TNF Inhibitor Therapy

The biomarker C6M was developed by Nordic Bioscience, and the biomarker measurements were sponsored by Nordic Bioscience.

0586: Drug Concentrations and Anti-drug Antibodies Influence in Response to
Adalimumab: Results from the BioEfficacySpA Clinical Trial
This project received a grant from Abbvie

0588: The Gut Enthesis Axis Coming into Focus with the Description of Enriched Enthesal Resident Mucosal Associated Invariant T-cells (MAITs) Capable of IL17A and TNF Production
RJC is supported by a Pfizer investigator initiated research grant, CB is supported by a Novartis Global research grant. neither Pfizer or Novartis took any part in collection analysis or interpretation of the data

0590: What Is the Impact of MRI on the Performance of the ASAS Classification Criteria in Patients Presenting with Undiagnosed Back Pain?
This study was supported by unrestricted funding from Abbvie. The sponsor had no role in the conduct or reporting of the study.

0593: Performance of the ASAS Classification Criteria Presenting with Undiagnosed Back Pain: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort
The study was supported by unrestricted funding from Abbvie. The sponsor had no role in the conduct or reporting of the study.

0594: Enhanced Performance of the ASAS Classification Criteria by Deletion of Non-Discriminatory Clinical Items: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort
The study was supported by unrestricted funding from Abbvie. The sponsor had no role in the conduct or reporting of the study.

0600: Frequency of Disease Flares Under Long-Term Anti-TNF Therapy in Patients with Early Axial Spondyloarthritis: Results from the Etanercept versus Sulfasalazine in Early Axial Spondyloarthritis Trial (ESTHER)
The ESTHER study was supported by an unrestricted research grant from Pfizer.

0601: Development of an Optimized Online Self-Referral Tool for Early Recognition of Patients with Axial Spondyloarthritis - Data from the OptiRef Study
The OptiRef project was supported by an unrestricted research grant from Novartis.

0602: Comparison of Men and Women with Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
This study was sponsored by Corrona, LLC. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the abstract. Support for third-party writing assistance for this abstract, furnished by Kheng Bekdache, PhD, of Health Interactions, Inc, was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ.

0610: Ankylosing Spondylitis-associated Killer Immunoglobulin-like Receptors Are Strongly Expressed on γδ T Cells
The study was partially funded by a research grant from Pfizer. The company had no role in the design or analysis of the study.

0614: Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data
This study was supported by Pfizer Inc.

0616: Association of Clinical and Radiographic Phenotype of Axial Spondyloarthritis and Skin Psoriasis: Results from the German Spondyloarthritis Inception Cohort
GESPIC has been financially supported by the German Federal Ministry of Education and Research (BMBF). As funding by BMBF was reduced in 2005 and stopped in 2007, complementary financial support has been obtained also from Abbott / Abbvie, Amgen, Centocor, Schering-Plough, and Wyeth. Since 2010 GESPIC is supported by Abbvie.

0617: Peripheral Involvement Is Associated with Less Radiographic Spinal Progression in Patients with Early Axial Spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort
GESPIC has been financially supported by the German Federal Ministry of Education and Research (BMBF). As funding by BMBF was reduced in 2005 and stopped in 2007, complementary financial support has been obtained also from Abbott / Abbvie, Amgen, Centocor, Schering-Plough, and Wyeth. Since 2010 GESPIC is supported by Abbvie.

0626: Are There Really Differences Between Non-radiographic and Radiographic Axial Spondyloarthritis? Data from the Spanish Atlas
This study was funded by Novartis Pharma AG

0629: Gender Differences in Comorbidities and Treatment Utilization Among Ankylosing Spondylitis Patients Initiating a Biologic in a Real-World Setting
This study was funded by UCB Pharma.

0630: Assessing the Humanistic and Economic Burden of Enthesitis Among Patients with Peripheral and Axial Spondyloarthritis: Results from a Multi-National Real World Survey Database
The study was funded by Novartis Pharma AG, Basel, Switzerland.

0631: Recognition of Inflammatory Back Pain by US Healthcare Providers and Barriers to Specialist Referral
This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ.

0644: Decreased HVEM Expression in Lupus Patients and Impact of HVEM Knockout Mouse Model of Lupus Suggest a Role for BTLA Signaling in Disease Pathogenesis
This study was funded by Eli Lilly and Company

0662: Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus
This was not a study evaluating a drug. The study sponsor supported the development and testing of a mobile app and intends to make both the data and the app available to other investigators and the public.

0669: Complement Activation in Probable Systemic Lupus Erythematosus (pSLE) May Predict Progression to SLE Defined by Fulfillment of ACR Classification Criteria
EXAGEN, Inc designed the study with the assistance of the investigators. It funded the
study, supervised the trial with a clinical research coordinator, performed all the laboratory tests (CLIA laboratory) and did the data analysis. All results have been reviewed by the principal investigator and the other investigators. Exagen, Inc markets cell-bound complement activation products and other tests for clinical use in lupus diagnosis and monitoring.

0676: Cluster Profiling of Patients in a Real-World Data Set with Systemic Lupus Erythematosus and Their Associated Treatments. Janssen Scientific Affairs, LLC supported this study.

0689: Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus. This study is supported by an industry research grant from Merck, to examine the role of High Disease Activity Status in SLE. The design, conduct, and reporting of the study are wholly responsibility of Monash University.

0703: Prior Knowledge Feature Reduction Improves Performance in a Machine Learning Model of Systemic Lupus Erythematosus Flare Status Using Serum Proteomics. This study was sponsored and conducted by PatientsLikeMe, Inc.

0708: Improvement and Stabilization of Lung Function in Patients with SSc-ILD Treated with Nintedanib vs Placebo in a Randomized, Placebo-Controlled Phase III Trial: Proportions of Patients with FVC Changes Using Cutoffs Previously Proposed to Define Minimally Clinically Important Differences. This study was sponsored by Boehringer Ingelheim International GmbH. Medical writing assistance was provided by John Carron of Nucleus Global, funded by Boehringer Ingelheim International GmbH.

0712: Safety and Tolerability of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis Based on Demographic Characteristics. Funded by Boehringer Ingelheim.

0720: Baseline Subject Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum in Diffuse Cutaneous Systemic Sclerosis. Staff from the funding source Corbus Pharmaceuticals, Inc. contributed to the study design, monitored and collected the data from sites and central laboratories, generated statistical analyses of the data, and contributed to this abstract.

0784: Application of Systems Biology-Based In Silico Tools for Optimal Treatment Strategy Identification in Still’s Disease. This study was supported by Novartis. No other sources of support were received, either financial or in kind. Novartis has developed this project with the support of Sudler - Anaxomics.

0802: Canakinumab Improves Patient-Reported Outcomes in Patients with Recurrent Fever Syndromes: Results from a Phase 3 Trial. The study was sponsored by Novartis Pharma AG, Basel, Switzerland.

0807: Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study.
This study was supported by Janssen Research & Development, LLC

**0808**: Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial

*F. Hoffmann-La Roche Ltd funded the study and analysis and was involved in writing the abstract.*

**0827**: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome

*This study was funded in full by Tonix Pharmaceuticals Inc.*

**0833**: Effect of a Mobile App to Monitor Patient Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial

*This abstract was funded by a grant from Pfizer. Pfizer did not play any role in the conduct and reporting of this study.*

**0835**: High Baseline Patient’s Compared with Evaluator’s Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients - Data from the EuroSpA Research Collaboration Network

*The EuroSpA Research Collaboration Network was financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, abstract preparation or decision to submit.*

**0836**: Patient-Reported Outcomes from a Randomised, Open-Label, Parallel-Group Study Evaluating Ixekizumab versus Adalimumab in Patients with PsA Who Are Biologic DMARD Naïve: 24-Week Results

*This study was sponsored by Eli Lilly and Company*

**0837**: Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network

*The EuroSpA Research Collaboration Network was financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, abstract preparation or decision to submit.*

**0844**: Impact of Glucocorticoid Tapering on Markers of Bone Metabolism in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab: Exploratory Analysis from a Randomized Controlled Trial

*F. Hoffmann-La Roche Ltd funded the study and analysis and was involved in writing the abstract.*

**0846**: MACE and VTE Across Multiple Upadacitinib Studies in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program

*AbbVie, Inc was the study sponsor, contributed to study design, data collection, analysis, interpretation, writing, reviewing, and approval of the final version of the abstract.*

**0847**: Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis

*The study was sponsored by Eli Lilly and Company, under license from Incyte Corporation.*
Ileal but Not Colonic Inflammation Is Linked to Fatty Lesions on MRI of the Sacroiliac Joints in Spondyloarthritis Patients

The Be-Giant consortium is supported by AbbVie

Do Smoking and Socio-economic Factors Independently Influence Imaging Outcomes in Axial Spondyloarthritis? Five-year Data from the DESIR Cohort

DESIR is financially supported by an unrestricted grant from Pfizer France

Adverse Events of Special Interest, SLE Medication Utilization, Hospitalizations, and Organ Damage: Results from a Phase 4, Randomized, Double-Blind, Placebo-Controlled, 52-week Study of Belimumab in Adults with Active, Autoantibody-Positive SLE

GlaxoSmithKline (GSK) designed, conducted, and funded the study, contributed to the collection, analysis, and interpretation of the data, and supported the authors in the development of the abstract. All authors, including those employed by GSK, approved the content of the submitted abstract. GSK is committed to publicly disclosing the results of GSK-sponsored clinical research that evaluates GSK medicines and, as such, was involved in the decision and to submit the abstract for publication.

Cutaneous Lupus Erythematosus Disease Area & Severity Index (CLASI) Demonstrates Thresholds for Detection of Treatment Response in a Phase-2, Placebo-Controlled Trial of Ustekinumab in SLE

Janssen Research & Development, LLC supported this study

Efficacy of Belimumab in Patients of Black Race with Systemic Lupus Erythematosus and High Disease Activity or Renal Manifestations

GlaxoSmithKline (GSK) designed, conducted, and funded the study, contributed to the collection, analysis, and interpretation of the data, and supported the authors in the development of the abstract. All authors, including those employed by GSK, approved the content of the submitted abstract. GSK is committed to publicly disclosing the results of GSK-sponsored clinical research that evaluates GSK medicines and, as such, was involved in the decision and to submit the abstract for publication.

First Use of Cenerimod, a Selective sphingosine-1-phosphate 1 (S1P1) Receptor Modulator, for the Treatment of Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase II, Proof-of-Concept Study

This study was sponsored by Actelion Pharmaceuticals Ltd. Study sponsorship was transferred to Idorsia Pharmaceuticals Ltd in July 2018. The Sponsor (initially Actelion Pharmaceuticals Ltd, then Idorsia Pharmaceuticals Ltd) participated in the design and conduct of the study, collection, management, analysis, and interpretation of the data.

Efficacy of Belimumab in Patients of Black Race with Systemic Lupus Erythematosus and High Disease Activity or Renal Manifestations—Results of Phase I/II Investigator-Initiated, Double-Blind Randomized Placebo-Controlled Trial

The trial was funded by an investigator-initiated study by Pfizer, Inc

Change in Scleroderma Skin Histology Correlates with the Combined Response Index in Systemic Sclerosis (CRISS) in Patients with Early, Diffuse Cutaneous Systemic Sclerosis

This study utilizes data from the nilotinib and belimumab trials in systemic sclerosis that were investigator-initiated studies supported by
research grants from Novartis and GlaxoSmithKline, respectively.

0865: Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Staff from the funding source Corbus Pharmaceuticals, Inc. contributed to the study design, monitored and collected the data from sites and central laboratories, generated statistical analyses of the data, and contributed to this abstract.

0882: Serum Anti-Vimentin Autoantibodies May Uniquely Predict Response to Therapy in Lupus Nephritis
Genentech provided serum samples from their LUNAR study. They also provided data from that study and statistical and clinical interpretation expertise. The serological analysis was performed at, and by researchers at the University of Chicago.

0891: Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation
Samumed, LLC designed, funded, and monitored the study. Samumed also conducted data management and statistical analysis.

AstraZeneca funded this study with employees providing input into the design, implementation, and analysis of the results of the study

0911: Perfusion in Bone Marrow Lesions Assessed on Dynamic Contrast-enhanced MRI and Its Association with Pain in Knee Osteoarthritis: A Cross-sectional Study
The LOSEIT trial was initiated by the Parker Institute and supported by Cambridge Weight Plan UK and Novo Nordisk A/S. None of the funders influenced the study design, collection, analysis and interpretation of data, writing, or the decision to submit the manuscript for publication.

0912: Co-morbidities Associated with Discordance Between Structural Severity and Pain in Osteoarthritis: Implications for Clinical Trial Design in OA – a Post-Hoc Analysis of Data from Two Randomized Controlled Trials
Novartis and Nordic Bioscience co-sponsored the studies.

0924: Highly-sensitive Cardiac Troponin-I and Beta-2-Glycoprotein-I IgA Antibodies Inform the Utility of Screening and Follow-up Non-invasive Coronary Atherosclerosis Evaluation and Optimize Cardiovascular Risk Assessment in Rheumatoid Arthritis
Pfizer was the study sponsor through an ASPIRE grant. The sponsor only provided funding. There was no involvement in study design, data collection, analysis, or manuscript compilation.

0927: Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outcome Results
This study was sponsored by Gilead Sciences, Inc.

0928: Monotherapy with Upadacitinib in MTX-naïve Patients with Rheumatoid Arthritis: Results at 48 Weeks
AbbVie, Inc was the study sponsor, contributed to study design, data collection, analysis & interpretation, and to writing, reviewing, and approval of final version.

**0929:** Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study

*This study was funded by Genentech, Inc. (South San Francisco, CA, USA). Statistical analysis was conducted by biostatisticians at Genentech, Inc., in accordance with a pre-specified statistical analysis plan. Writing and editorial support was provided by Genentech, Inc.*

**0930:** Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator

*SetPoint Medical funded the study, contributed to the design, collection, analysis, and interpretation of the data, and in the writing, review, and approval of the abstract.*

**0932:** Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheumatoid Arthritis

**0935:** Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study

*This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.*

**0936:** Earlier Treatment of Non-Radiographic Axial Spondyloarthritis with Certolizumab Pegol Results in Improved Clinical and Patient-Reported Outcomes

This research was supported in part by Pfizer Inc. through an Investigator Initiated Research Grant and was limited to providing study drug

**0937:** Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study

*The abstract was sponsored by UCB Pharma*

**0938:** TNF Inhibitors Reduce Spinal Radiographic Progression in Axial Spondyloarthritis by Mechanisms Associated with but Also Independent of Disease Activity

*FORCAST was supported by an unrestricted grant from Abbvie.*

**0939:** A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis

*This study was funded by F. Hoffman-La Roche. F. Hoffman-La Roche was involved in the design and execution of the study and in the reporting of the study results.*

**0942:** A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus

*Exagen funded the study.*

**0943:** A Phase 1b/2a Trial of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

*This research was supported in part by Pfizer Inc.*
and placebo. The sponsor had no role in study design, conduct or reporting or results.

0944: Efficacy and Safety of Dapirolizumab Pegol in Patients with Moderately to Severely Active Systemic Lupus Erythematosus: A Randomized, Placebo-Controlled Study
This study was funded by UCB Pharma and Biogen. The authors acknowledge Teri Jimenez for the statistical analysis of interim data.
Editorial services were provided by Costello Medical, which was funded by UCB Pharma.

0946: Improvements in Disease Activity and Quality of Life for up to 64 Weeks in Patients with Behçet’s Syndrome: Results from a Phase III Study
This study was sponsored by Celgene Corporation.

0949: Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012–2016 US Medicare Data
Gilead Sciences, Inc. financially supported the study and participated in the planning, execution, and interpretation of the research.

0953: Discovery of DWP212525, a Potent JAK3 and BTK Dual Target Inhibitor for the Treatment of Autoimmune Diseases
Pharmaceutical company

0956: Discovering CJ-15314, a Novel Highly Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis
Authors are employees of Johnson & Johnson

0958: Stimulation of Splenic Neurovascular Bundle Protect Mice from Developing Collagen-induced Arthritis

Funding and support provided by Clarivate Analytics.

0964: Identification of Novel Genes Associated with Dysregulation of B Cells in Patients with Primary Sjögren's Syndrome
This study was funded by Takeda Pharmaceutical Company Limited and Keio University.

0966: Tofacitinib Enhanced Cerebral Brain-derived Neurotrophic Factor Levels in a Rat Model of Rheumatoid Arthritis
With an institutional support from Pfizer.

0986: Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis
All authors are employees of AbbVie. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.

0990: Development of a Novel Anti TNF-Steroid Antibody Drug Conjugate That Shows Promising Efficacy at Doses That Avoid Steroid Side Effects in a Mouse Model of Rheumatoid Arthritis
All authors are employees of AbbVie. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.

0992: Identification of CJ-15314, a Novel Highly Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis

0998: Stimulation of Splenic Neurovascular Bundle Protect Mice from Developing Collagen-induced Arthritis
The study sponsor was involved in designing the experiments, but data was analysed independent from the sponsor.

1010: NYX-2925 Impacts Functional and Chemical Neuroimaging Biomarkers and Patient-reported Outcomes of Pain in Patients with Fibromyalgia

This Phase II clinical trial was sponsored by Aptinyx Inc., Evanston, Illinois, USA. Aptinyx provided funding for subject recruitment and compensation, data collection and analysis, and study monitoring. Aptinyx provided all study drug. Data were collected at two academic medical centers by non-Aptinyx employees: University of Michigan and University of Cincinnati College of Medicine. Analysis of clinical effectiveness and safety data were conducted by Aptinyx and their affiliates. All neuroimaging data were pre-processed and analyzed by the University of Michigan, independent of Aptinyx.

1012: Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA

This study was sponsored and funded by UNITY Biotechnology, which also developed the investigational drug UBX0101 evaluated in the study. The presentation of this abstract was developed in collaboration with a medical communications vendor funded by the Study Sponsor. The Study Sponsor does not meet the ACCME definition of commercial interest because, at this time, UNITY Biotechnology is not an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

1013: Interferon-gamma (IFN-γ) Neutralization with Emapalumab and Time to Response in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (s-JIA) who failed High-Dose Glucocorticoids

1014: A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial

CZP and ABA were provided by the manufacturers at no cost. They had no influence on the study design, data collection, analysis or writing the abstract. They received the abstract prior to submission for comments (errors and patents). In addition, several unrestricted grants from BMS at the local level helped defray various trial-related costs.


Denmark: Regionernes Medicinpulje, NordForsk, BMS

Norway: HELSEFORSK (interregional grant), South-Eastern Norway Regional Health Authority, NordForsk

Finland: Academy of Finland, HUCH Institutional grant, Finska Läkaresällskapet

The Netherlands: BMS

Iceland: The research funds of the University Hospital, Reykjavik, Iceland, and the Society for Rheumatology of Iceland

1018: Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naive, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIib Study

Bristol-Myers Squibb was involved in design, conduct, analysis, and reporting of the study.
1033: Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate - CRED01 Study
Funding: R-Pharm International

1039: Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
This study was sponsored by Janssen Research & Development, LLC

1046: Tofacitinib as Monotherapy Following Methotrexate Withdrawal in Patients with Psoriatic Arthritis Previously Treated with Open-label Tofacitinib + Methotrexate: A Randomized, Placebo-controlled Sub-study of OPAL Balance
Company: Pfizer Inc
Describe the role of the Company in the Study: This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Christina Viegelmann, PhD, at CMC Connect, a division of McCann Health Medical Communications Ltd, Glasgow, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines

1052: Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial
This study was funded by Genentech, Inc., the sponsor. The sponsor and the authors were involved in the study design and/or conduct. The investigators and their respective research teams collected all the data. Statistical analyses were conducted by biostatisticians at Genentech, Inc., in accordance with a pre-specified statistical analysis plan. All authors participated in the analysis and interpretation of the data, reviewed and provided feedback on the abstract, and made the decision to submit the abstract. All authors vouch for the completeness and accuracy of the data and analyses.

1054: Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
AstraZeneca funded this study with employees providing input into the design, implementation, and analysis of the results of the study.

1059: A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study
RemeGen, LTD sponsored the clinical study and is developing Telitacicept as a potential novel therapeutic for the treatment of B-cell mediated autoimmune disorders. [Note to ACR: Please advise if additional statements or information are typically included here. We are happy to provide whatever is customarily involved. Many thanks!]

1062: Iналумаб (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients
The study was sponsored by Novartis Pharma AG, Basel, Switzerland
1063: A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
This study was funded by Eli Lilly and Company. Eli Lilly and Company was responsible for funding, conduct, and reporting of the study.

1064: Novel Computer Assisted Methodology for Quantitative Assessment of MRI Treatment Responses to Apremilast in Patients with Psoriatic Arthritis
The study was sponsored by Novartis Pharma AG. Academic advisors and Novartis personnel designed the study. Novartis conducted the data analyses. All authors had access to the data and vouch for the completeness and accuracy of the data and analyses.

1067: Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study
This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Sarah Piggott, MChem, at CMC Connect, a division of McCann Health Medical Communications Ltd, Glasgow, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

1073: IL-17A Induces Distinct Functional Differences Between Two Novel Mesenchymal Stem Cell Populations Identified at the Human Enthesis
PhD Project funded by Novartis

1074: Apremilast Inhibits Immune Cells Support of Inflammatory Osteoclastogenesis
Supported by Celgene PARTNER Fellowship; Celgene had no further role in data generation, analysis and presentation.

1076: Effects of Anti-TNF on MiR Expression in Monocytes and CD4+ T-Lymphocytes in Spondyloarthritis
MSD Avenir and Pfizer Passerelle: grant research only

1077: Regulatory Role of IL-23 and Its Receptor System in Spondyloarthritis and Its Therapeutic Relevance in anti-IL-17 Failure Patients
This study was funded by the Sun Pharmaceutical Industries Limited

1079: Renal Single Cell Genomics Links Type II Interferon and Lupus Nephritis in African-Americans
This work was supported by the Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network. AMP is a public-private partnership (AbbVie Inc., Arthritis Foundation, Bristol-Myers Squibb Company, Lupus Foundation of America, Lupus Research Alliance, Merck Sharp & Dohme Corp., National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Pfizer Inc., Rheumatology Research Foundation, Sanofi and Takeda Pharmaceuticals International, Inc.) created to develop new ways of identifying and validating promising biological targets for diagnostics and drug development. Funding was provided through grants from the National Institutes of Health (UH2-AR067676, UH2-AR067677, UH2-AR067679, UH2-AR067681, UH2-AR067685, UH2-AR067688, UH2-AR067689, UH2-AR067690, UH2-AR067691, UH2-AR067694, and UM2-AR067678).
1081: Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus
Support for patient recruitment and CyTOF data acquisition were supported by Merck.

1083: Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study
The study was sponsored by Eli Lilly and Company, under license from Incyte Corporation. The study sponsor designed the study, and provided data analysis and laboratory and site-monitoring services.

1084: The Effect of Nintedanib versus Mycoheolate Mofetil in the FRA2 Mouse Model of Systemic Sclerosis Associated Interstitial Lung Disease
The study was funded by Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

1086: The PPAR Agonist Lanifibranor Protects Against Right Ventricular Hypertrophy in a Mouse Model of Systemic Sclerosis Associated Pulmonary Hypertension
This project was supported by a grant from Inventiva who were not involved in study design or data analysis.

1088: Analysis of Serum Markers Across the Scleroderma Spectrum Shows Subset and Stage Specific Profiles of Fibrogenesis
GlaxoSmithKline funded the processing of serum and plasma samples

1098: BDCA2 Targeting of Human Plasmacytoid Dendritic Cells via CBS004 Reverts Dependent IFN Activation and Tissue Fibrosis in vitro and in vivo
The study has been funded by a Research Grant by Capella biosciences LTD. Capella biosciences was involved into the design of the studies but played no role in the conduct or reporting of the study.

1101: Lymphocyte Subset Abnormalities in Early Diffuse Cutaneous Systemic Sclerosis
Role of the Study Sponsors: this study was funded by the NIH and Bristol-Myers-Squibb

1102: Effects of Abatacept on T Regulatory Cells in Early Diffuse Systemic Sclerosis
Role of the Study Sponsors: This study was funded by the NIH and by Bristol-Myers-Squibb

1103: CD123+ Plasmacytoid Dendritic Cells from Systemic Sclerosis Patients Are Susceptible to the Cytotoxic Activity of Tagraxofusp, a CD123-Targeted Therapy
This research was sponsored by Stemline Therapeutics.

1108: Cytokine Signatures Differentiate Systemic Sclerosis Patients at High versus Low Risk for Pulmonary Arterial Hypertension
Research funding for PHAROS was received from Gilead and Actelion, however neither company had any role in study design, data collection, or data analysis.

1113: Identification of Distinct Pro-Fibrotic Monocyte and Macrophage Subsets in Systemic Sclerosis
Role of study sponsors included experimental design and analysis.

1116: Incidence of Non-serious Infections Among Live Born Infants Born to Mothers Who Used Biologic Medications During Pregnancy for the Treatment of Autoimmune Diseases
Sponsors had no role in the abstract.

1118: Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications
Sponsors had no role in the abstract.

1124: Assessing Psoriatic Arthritis Treatment Trends and Patient Journeys Between 2012 and 2018
This study was sponsored by Celgene Corporation.

1125: Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
This study was sponsored by Corrona, LLC.
Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the abstract. Support for third-party writing assistance for this abstract, furnished by Elizabeth Ohneck, PhD, of Health Interactions, Inc, was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ.

1129: Patient Reported Outcomes over Time in 25,988 Axial Spondyloarthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Clinical Practice – Is PRO Remission Achieved? Results from the EuroSpA Collaboration
The EuroSpA Research Collaboration Network is financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, abstract preparation or decision to submit.

1135: Predicting ASDAS Inactive Disease After 6 Months of TNFi Treatment in Bio-Naive Axial Spondyloarthritis Patients Treated in Clinical Practice – Results from the EuroSpA Collaboration
The EuroSpA Research Collaboration Network is financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, abstract preparation or decision to submit.

1149: Psoriatic Arthritis - Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis
This analysis was funded by Novartis Pharma GmbH

1164: Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? – Results from the EuroSpA Research Collaboration
The EuroSpA Research Collaboration Network is financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, abstract preparation or decision to submit.
1171: Epidemiology and Mortality of SLE (Systemic Lupus Erythematosus) in Hungary Based on a Nationwide Retrospective Claims Database Study

Janssen has an interest in several immunological disorders, including SLE and are currently developing innovative compounds in this field. The related study will add new scientific knowledge in SLE with regards to treatment patterns and survival.

1173: Development of an Algorithm to Identify Sjögren’s Syndrome Patients in the French National Healthcare Claims Database

This study was sponsored by Bristol-Myers Squibb.

1175: Estimate of Prevalence of Secondary Distal Renal Tubular Acidosis Among Patients with Sjögren’s Syndrome and Systemic Lupus Erythematosus in a US Population with Employer-Sponsored Health Insurance

This study was sponsored by Adicenne.

1180: Prevalence of Diagnosed Systemic Lupus Erythematosus (SLE), Patient Healthcare Utilization and Characteristics by Major Health Insurance Types in the US

All authors are employees of a pharmaceutical company.

1183: Mobile Apps in Rheumatology: Review and Analysis Using the Mobile App Rating Scale (MARS)

This work was supported by Pfizer GmbH, Germany

1184: Improving Healthcare Quality and Reducing Cost via Online Interaction for Chinese Patients with Rheumatic Diseases Based on

Smart System of Disease Management (SSDM) Mobile Tool

The Smart System Of Disease Management (SSDM) was developed by Shanghai Gothic Internet Technology Co., Ltd.

1202: Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab (REMICADE)

This study was funded by Janssen Scientific Affairs, LLC. The study sponsor was involved in all aspects of the research, including the conception and design of the study; the collection, analysis, and interpretation of the data; writing of the abstract; and the decision to submit the abstract to the conference.

1203: Non-medical Switching from Reference to Biosimilar Etanercept - No Evidence for Nocebo Effect – a Retrospective Analysis of Real-life Data

Biogen GmbH funded this research. The Investigators retained full control of scientific and analytic content, and had final editorial responsibility.

1204: US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation

This study was sponsored by Cardinal Health Specialty Solutions.

1205: The Direct and Indirect Costs of Illness Associated with Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review

Janssen Scientific Affairs, LLC supported this study.

1212: Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic
Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs

This study is conducted by the employees of Bristol-Meyers Squibb.

1215: Direct Medical and Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States

Pfizer Inc. and Dr. Elena Losina crafted the research questions. Pfizer Inc. reviewed and approved this abstract.

1216: Optimizing the Management of Flares in Patients with Rheumatoid Arthritis with the Help of Non-Physician Providers: Results of a Randomized Controlled Trial

This work was supported by a grant from Pfizer (Grant ID 15322005). Funders reviewed the protocol for the study but had no role in study conduct or interpretation of the results.

1217: Are There Country Differences in Disease Activity and Life Impact of Psoriatic Arthritis? An Analysis of 436 Patients from 14 Countries

The ReFlaP study was funded by Pfizer through an investigator initiated research grant. Pfizer played no role in the study design, data collection, analysis or interpretation and did not have access to this abstract before submission.

1218: Novel Computer Assisted Methodology for Quantitative Assessment of MRI Treatment Responses to Apremilast in Patients with Psoriatic Arthritis

Study sponsor provide the drug and funded running the study and the statistical analysis

1221: Evidence of Subclinical Joint Inflammation of Hands by Magnetic Resonance Imaging in Patients with Psoriatic Arthritis in Minimal Disease Activity – Interim Analysis

Role of the study sponsor: Janssen Pharmaceutica has sponsored the cost of hand MRI studies.

1223: Magnetic Resonance Imaging in Patients in Clinical Remission: Tenosynovitis and Osteitis Are Independent Predictors of Radiographic and MRI Damage Progression

Grant support for this investigator-initiated study from AbbVie was paid to our institution (Rigshospitalet). AbbVie had no role in the design and conduct of the trial; collection, management, analysis, and interpretation of the data; the decision to submit for publication or preparation, review, or approval of the manuscript for publication.

1224: Periarticular Inflammation and Bone Marrow Oedema Are Important in the Evaluation of Enthesitis on MRI in Patients with Peripheral and Axial SpA

The study was sponsored by Novartis Pharma AG. Academic advisors and Novartis personnel designed the study. Novartis conducted the data analyses. All authors had access to the data and vouch for the completeness and accuracy of the data and analyses.

1229: Confirmation of Manual Cartilage Segmentation Findings by Automated Segmentation: Retrospective Analysis of MRI Images from a Sprifermin Phase II Study

This study is sponsored by Merck KGaA, Darmstadt, Germany. The study sponsor was involved in the study design, collection, analysis, and interpretation of data, and was involved in the decision to submit the abstract for publication.

1231: Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium
Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study

Supported by an investigator-initiated grant from Horizon Pharma.

1235: Rheumatoid Arthritis Activity Assessment with Cellphone Thermal Camera Imaging Compared to Clinical and Ultrasound Assessments

Unrestricted grant from Abbvie

1236: Testing Rheumatoid Arthritis Performance Measures to Optimize Treat to Target Strategies

The Rheum4U platform was supported by unrestricted educational grants from Abbvie, Amgen, Bristol-Myers Squibb (BMS), Celgene, Pfizer, Roche, Sanofi, Swedish Orphan Biovitrum AB (Sobi), and Union Chimique Belge (UCB). These commercial enterprises played no role in the conduct or reporting of the study.

1237: Psychometric Properties of the Patient Related Outcome Measure FACIT-Fatigue in Rheumatic Arthritis and Psoriatic Arthritis: A Literature Review

This study was sponsored by Janssen Scientific Affairs, LLC

1240: Improvements in Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody: 1-Year Results of a Phase III Trial

Janssen Research & Development, LLC supported this study.

1254: Real-World Remission Outcomes in the First Year Following RA Diagnosis Vary Considerably with the Disease Activity Index Used and a Sizable Proportion Have Persistent Active Disease Across All Measures: Results from the Canadian Early Arthritis Cohort (CATCH)

The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017 and Sandoz Canada, Biopharmaceuticals since 2019. Previously funded by Hoffmann-LaRoche and Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017.

1257: Psychological Profile in Patients with Rheumatic Diseases in China: A Study of HADS Self-assessment with Smart System of Disease Management (SSDM)

Smart system of disease management (SSDM) was developed by Shanghai Gothic Internet Technology Co., Ltd.

1258: A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-Ranging Study to Evaluate Efficacy and Tolerability of SHR4640 in Patients with Hyperuricemia

This study was sponsored by Jiangsu Hengrui Medicine Co., Ltd. The sponsor worked with the principal investigator to design the study. Data collection and interpretation, and preparation of this report, were done by all investigators and the sponsor. Statistical analyses were performed by the sponsor.

1279: Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy AndSafety Study of a Transdermal Alkalinizing and Pain Relieving Treatment ForAcute Gout Flare

The sponsor provided financial support to the investigational sites to conduct the study. The
sponsor also provided a regulatory compliance electronic data capture system for the sites to input data. The sponsor also provided funding to a third-party firm to conduct the statistical analysis of the data.

1298: Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development
Sponsored by: Selecta Biosciences, Inc. Selecta Biosciences designed the study and collected, analyzed, and interpreted the data

1302: Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients
Sponsored by: Selecta Biosciences, Inc. Selecta Biosciences designed the study and collected, analyzed, and interpreted the data.

1303: Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis - A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab
Novartis applied the data and financed the statistical work

1304: Enteral Administration of ALLN-346, a Recombinant Urate-degrading Enzyme, Decreases Serum Urate in a Pig Model of Hyperuricemia
This abstract was supported by Allena Pharmaceuticals

1307: AR882, a Potent and Selective URAT1 Inhibitor with a Favorable Pharmacological, Pharmacokinetic and Toxicity Profile
This abstract is sponsored and funded by Arthrosi Therapeutics, Inc., 23052 Alcalde Dr, Suite A, Laguna Hills, CA 92653

1308: AR882, a Potent and Selective Uric Acid Lowering Agent Acting Through Inhibition of Uric Acid Reuptake, Shows Excellent Pharmacokinetics and Pharmacodynamics in a Phase 1 Clinical Trial
This study was sponsored by Arthrosi Therapeutics, California.

1309: Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase
This work was supported by Horizon.

1318: Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Mitigates Formation of Anti-Drug Antibodies Resulting in Sustained Uricase Activity in Symptomatic Gout Patients
Sponsored by: Selecta Biosciences, Inc. Selecta Biosciences designed the study and collected, analyzed, and interpreted the data.

1322: Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice
Horizon funded the collection of retrospective de-identified chart data for this project.

1325: Treatment with OLT1177™, an Oral NLRP3 Inflammasome Inhibitor, Reduces Systemic Inflammation During Gout Flares in Humans
The phase II clinical trial of which data is presented in this abstract was sponsored by Olatec

1326: A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-
To-Treat Acute Gouty Arthritis: The anaGO Study
This study was fully funded by Sobi, which is the study sponsor. An external panel of scientific experts were included in developing the study design together with Sobi. The study was conducted by external investigators in different clinics. Sobi was responsible for data analysis and is responsible for reporting the study outcome to authorities.

1327: A Retrospective Medical Chart Review of Patients with Periodic Fever Syndromes Initiating Canakinumab in the United States
The study was funded by Novartis Pharmaceuticals Corporation, USA.

1329: Recommendation on Colchicine Dosing and Definition of Colchicine Resistance/Intolerance in the Management of Familial Mediterranean Fever
Submission support for this abstract was provided by Seren Communications, funding for which was provided by Novartis Pharma AG

1330: Effects of Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody, on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 1-Year Results of a Phase III Trial
This study was sponsored by Janssen Research & Development, LLC.

1331: Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management

1332: A Randomised Clinical Trial of Curcuma Longa Extract for Treating Symptoms and Effusion-Synovitis of Knee Osteoarthritis
This investigator-initiated clinical trial was sponsored by the University of Tasmania and partially funded by Institutional funds (Menzies Institute for Medical Research, University of Tasmania) and a natural products company (Natural Remedies Pvt. Ltd, Bengaluru). The company supplied the Curcuma longa extract and placebo capsules according to the investigator’s requirements. The company did not have any role in the design, implementation or data analyses of the study. None of the investigators ever received any other financial support from the company.

1336: Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
This study was sponsored by Pfizer and Eli Lilly and Company, which were involved in the design, conduct, and/or analysis of the study.

1338: Intra-Articular TPX-100 Significantly Delays Pathological Bone Shape Change at 6 and 12 Months in Moderate to Severe Tibiofemoral OA
The study was sponsored by OrthoTrophix, Inc. Study site, data management and clinical study reports were provided by a contract research organization.

1341: Efficacy and Safety of Hylan G-F 20 versus Intra-Articular Corticosteroids in Patients with Knee Osteoarthritis: A Systematic Literature Review, Meta-Analysis, and Network Meta-analysis
This analysis was funded by Sanofi. Doctor Evidence was contracted to conduct this analysis.
**1344:** A Prospective, Multi-center, Randomized, Clinical Trial Comparing the Effectiveness and Safety of Cooled Radiofrequency Ablation versus a Single Injection of Hyaluronic Acid in the Management of OA Knee Pain

*Portions of this clinical trial were funded by Avanos Medica, INC*

**1348:** Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes

*Samumed, LLC designed, funded, and monitored the study. Samumed also conducted data management and statistical analysis.*

**1350:** Concordance of Baseline Pain Measures (Across Two Reporting Instruments) Influences Treatment Effect: Post Hoc Analysis of a Phase 3 Randomized Controlled Trial of Triamcinolone Acetonide Extended-Release in Patients with Knee Osteoarthritis

*This study was funded by Flexion Therapeutics, Inc. (Burlington, MA, USA).*

**1351:** In an International, Multicentre, Double-blind, Randomised Study in Knee Osteoarthritis Patients, Diacerein Was Found as Effective as Celecoxib in Reducing Pain and Disease Symptoms

*This study was funded by TRB Chemedica International SA, the manufacturer of diacerein. TRB was involved in the design of the study*

**1352:** Evaluation of Intra-articular CNTX-4975 in Subjects with Painful Bilateral Knee Osteoarthritis: Effects on Pain with Walking and Patient Impression of Change in Pain

*Funding provided by Centrexion Therapeutics Corp*

**1355:** Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Japanese Subjects of the ADAMTS-5 Inhibitor S201086/GLPG1972, a Potential New Treatment in OA

*This abstract reports results of a study funded by Institut de Recherches Internationales Servier, Suresnes, France.*

**1365:** Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis

*Samumed, LLC designed, funded, and monitored the study. Samumed also conducted data management and statistical analysis.*

**1370:** The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial

*Samumed, LLC designed, funded, and monitored the study. Samumed also conducted data management and statistical analysis.*

**1371:** Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis

*The sponsor (Gilead Sciences, Inc.) participated in the FINCH-2 trial design, and was responsible for coordinating the collection, management and analysis of the data. The academic authors and sponsor coauthors were responsible for drafting, editing, and revising of the abstract*

**1374:** No Difference in Treatment Continuation of Different Biologics in Elderly Patients > 70 Years Compared to Younger Patients ≤ 65 Years
RABBIT is supported by a joint, unconditional grant from AbbVie, Amgen, Bristol-Myers Squibb, Celltrion, Hexal, Lilly, MSD Sharp & Dohme, Mylan, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis and UCB.

1375: No Confirmation of Increased Risk of Idiopathic Facial Nerve Palsy Under Tocilizumab

RABBIT is supported by a joint, unconditional grant from AbbVie, Amgen, Bristol-Myers Squibb, Celltrion, Hexal, Lilly, MSD Sharp & Dohme, Mylan, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis and UCB

1376: United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization

This study was sponsored by Janssen Scientific Affairs, LLC

1377: Systematic Literature Review and Meta-Analysis of DAS28 Clinical Response Rates Among Advanced Therapies in Biologic-Naive Patients with Rheumatoid Arthritis

This study was sponsored by AbbVie. The design, study conduct, and financial support for the study was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract.

1378: Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start

This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Kirsten Woollocott, MSc, at CMC Connect, a division of McCann Health Medical Communications Ltd, Glasgow, UK and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

1379: Impact of Tocilizumab on Anxiety and Depression in Patients with Rheumatoid Arthritis

This study was supported by Roche Pharmaceuticals (Israel) Ltd., Hod Hasharon, Israel.

1380: Increased High Molecular Weight Adiponectin and Lean Mass During Tocilizumab Treatment in Patients with Rheumatoid Arthritis: A 12 Month Multicenter Study

Role of the sponsor: funding support. Not involved in the study design, acquisition and interpretation of the data

1383: Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials

This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Kirsten Woollocott, MSc, at CMC Connect, a division of McCann Health Medical Communications Ltd, Glasgow, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

1384: Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs

The study was sponsored by Eli Lilly and Company, under license from Incyte Corporation. The study sponsor designed the
study and provided data analysis, laboratory and site-monitoring services, and writing support.

1386: Mortality of Rheumatoid Arthritis Patients, Treated to Target at Low Disease Activity: 17-years Follow-up of the BeSt Cohort

This study was funded by a grant from the Dutch College of Health Insurances (College Voor Zorgverzekeringen). Schering-Plough BV and Centocor Inc. provided additional funding and supplied the medication for patients in initial treatment arm 4. The funding sources had no role in study design; collection, analyses, and interpretation of all data.

1387: Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies

Financial support for the study was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. All authors participated in the interpretation of data, critical review of the drafts, development of the publication, and maintained control over the final content.

1388: A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures

Work supported through a grant from Amgen Corporation

1389: Construct Validation of PROMIS Short Form and Profile-29 T-Scores with SF-36 in Rheumatoid Arthritis Patients Treated for 1 Year: Results from a Real World Evidence-Based Study in the United States

This study was sponsored by Janssen Scientific Affairs, LLC

1391: Not All Joints Are Equal: Challenge DAS28 System and Identify Factors Leading to a Mismatch Between T2T and HAQ Among RA Patients Through Data Mining from Smart System of Disease Management (SSDM)

Smart System of Disease Management (SSDM) was developed by Shanghai Gothic Internet Technology Co., Ltd.

1392: Create an Algorithm of Outcome Forecasting and Decision Making for RA Treatment: Data Mining and Machine Learning via the Smart System of Disease Management (SSDM)

Smart system of disease management (SSDM) was developed by Shanghai Gothic Internet Technology Co., Ltd.

1393: Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US

Gilead Sciences, Inc. financially supported the study and participated in the planning, execution, and interpretation of the research.

1394: Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study

Financial support for the study was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. All authors participated in the interpretation of data, critical review of the
drafts, development of the publication, and maintained control over the final content.

**1396:** Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials

*Financial support for the study was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. All authors participated in the interpretation of data, critical review of the drafts, development of the publication, and maintained control over the final content.*

**1397:** MTX Withdrawal in Patients with RA Who Achieve Low Disease Activity with Tofacitinib Modified-Release 11 Mg Once Daily + MTX: An Assessment of the Impact on the Short Form-36 Patient-Reported Outcome

*This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Jennifer Arnold, PhD, at CMC Connect, a division of McCann Health Medical Communications Inc, Radnor, PA, USA, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).*

**1398:** High Baseline Serum IL-6 Predicts Increased Sarilumab Treatment Response for Patient Reported Symptoms and Health-Related Quality of Life Among Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate

*Medical writing support provided by Prime, Knutsford, Cheshire, UK, funded by Sanofi and Regeneron Pharmaceuticals, Inc.*

**1399:** Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study

*Study funding was provided by Sanofi and Regeneron Pharmaceuticals, Inc. Medical writing support (Laura George, Adelphi Communications Ltd) was funded by Sanofi.*

**1403:** Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry

*This study was sponsored by Corrona, LLC, and the analysis was funded by Gilead Sciences, Inc. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie; Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Crescendo; Eli Lilly and Company; Genentech; Gilead Sciences, Inc.; GSK; Janssen; Merck; Momenta Pharmaceuticals; Novartis; Ortho Dermatologics; Pfizer, Inc.; Regeneron; Roche; Sun Pharmaceutical Industries, Inc.; and UCB. Gilead Sciences, Inc. financially supported the study and participated in the planning, execution, and interpretation of the research.*

**1406:** Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from a Phase 3/4 Study

*F. Hoffmann-La Roche Ltd funded the study and analysis and was involved in writing the abstract.*

**1407:** Duration of Oral Corticosteroid Therapy Does Not Change with the Addition of a Parenteral Injection: Results from a Real-World Canadian Early RA Cohort
The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017 and Sandoz Canada, Biopharmaceuticals since 2019. Previously funded by Hoffmann-LaRoche and Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017.

1409: Association Between Baseline Anti-citrullinated Protein Antibody Status and Response to Abatacept or Non-TNF Inhibitor Therapy in Patients with RA: Results from a US National Observational Study
This study is sponsored by Corrona, LLC and funded by Bristol-Myers Squibb. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GlaxoSmithKline, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Pfizer Inc., Regeneron, Roche, Sun, UCB and Valeant. The design and study conduct were a collaborative effort between Corrona and Bristol-Myers Squibb, and financial support for the study was provided by Bristol-Myers Squibb.

1410: Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab
Study funding and editorial support (Sophie Albon, Adelphi Communications Ltd) were provided by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

1411: The Association Between Treatment of Abatacept or Other Target Disease-Modifying Anti-rheumatic Drugs and Type 2 Diabetes Mellitus (T2DM)-Related Healthcare Resource Utilization and Costs in Commercially Insured Rheumatoid Arthritis Patients with T2DM

1412: Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry
Bristol-Myers Squibb was involved in design, conduct, analysis, and reporting of the study.

1413: Connective Tissue Remodeling Is Differently Modulated by Tocilizumab versus Methotrexate Monotherapy in Patients with Early RA: The AMBITION Study

1414: Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab
Study funding and editorial support (Sophie Albon, Adelphi Communications Ltd) were provided by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

1415: The Relationship Between Abatacept Exposure and CD86 Receptor Occupancy in Rheumatoid Arthritis Patients Following Subcutaneous Administration and Its Association to Patient Outcomes
Bristol-Myers Squibb. The study sponsor provided funding for the completion of the study and the development of the abstract.

1416: Impact of Sarilumab on Unacceptable Pain and Inflammation Control in Moderately-to-Severely Active Rheumatoid Arthritis (RA) Patients in 3 Phase 3 Studies
The study was funded by Sanofi and Regeneron Pharmaceuticals, Inc.

1417: The Association Between Baseline Anti-CCP2 Antibody Concentration and Clinical Response After 6 Months of Treatment with Abatacept or a TNF Inhibitor in Biologic-Experienced Patients with RA: Results from a US National Observational Study
This study is sponsored by Corrona, LLC and funded by Bristol-Myers Squibb. Corrona has
been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GlaxoSmithKline, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Pfizer Inc., Regeneron, Roche, Sun, UCB and Valeant. The design and study conduct were a collaborative effort between Corrona and Bristol-Myers Squibb, and financial support for the study was provided by Bristol-Myers Squibb.

1419: Persistence of Tocilizumab Therapy Among Patients with Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry

This study was sponsored by Corrona, LLC, and the analysis was funded by Genentech, Inc. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analyses; all authors contributed to the interpretation of the results. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sun and UCB.

1420: Comparative Effectiveness of Tocilizumab in Combination with Methotrexate versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination with Methotrexate in Patients with Rheumatoid Arthritis with Prior Exposure to TNFis

This study was sponsored by Corrona, LLC, and the analysis was funded by Genentech, Inc. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analyses; all authors contributed to the interpretation of the results. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sun and UCB.

1421: Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)

Study funding and medical writing support (Helen Johns, Adelphi) provided by Sanofi and Regeneron Pharmaceuticals, Inc. These data were previously presented at the European Congress of Rheumatology (EULAR) 2019, Madrid, Spain.

1422: Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset

This study was sponsored by Pfizer Inc.

1423: CDAI Analysis of Dose Escalation in a Trial of Infliximab for Rheumatoid Arthritis

The START trial was sponsored by Janssen Research & Development, LLC.

1424: Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial U-Act-Early and U-Act-After where both funded by Roche Nederland BV
**1425:** Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis

The study was sponsored by Eli Lilly and Company, under license from Incyte Corporation. The study sponsor designed the study and provided data analysis, laboratory and site-monitoring services, and writing support.

**1426:** Comparison of Healthcare Resource Utilization and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Initiated Treatment with Abatacept versus Other Targeted Disease-Modifying Anti-Rheumatic Drugs

This study was sponsored by Bristol-Myers Squibb.

**1427:** Cycling of Tumor Necrosis Factor-α (TNF-α) Inhibitors versus Switching to Different Mechanism of Action in Rheumatoid Arthritis Patients with Inadequate Response to TNF-α Inhibitor: A Bayesian Network Meta-analysis

**1430:** Efficacy and Safety of Tofacitinib Modified-Release 11 Mg Once Daily + MTX in RA Patients with an Inadequate Response to MTX: Open-Label Phase Results from a Global Phase 3b/4 MTX Withdrawal Study

This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Jennifer Arnold, PhD, at CMC Connect, a division of McCann Health Medical Communications Inc, Radnor, PA, USA and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

**1431:** Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early (≤ 2 Years) vs Established (> 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy

This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Christina Viegelmann, PhD, at CMC Connect, a division of McCann Health Medical Communications Ltd, Glasgow, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

**1438:** Improvement of Mental Health and Quality of Life During Therapy with Tocilizumab

This study was supported by Roche Pharma AG (Grenzach-Wyhlen, Germany) and Chugai Pharma Germany GmbH (Frankfurt am Main, Germany)

**1439:** Effect of Tofacitinib on the Qualitative Profile of High Density Lipoproteins Molecules in Patients with Rheumatoid Arthritis

Study initiated by the researcher supported by Pfizer.

**1443:** Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Prospective Observational Registry

Janssen supported clinical trial

**1444:** Predictors of Response, Adverse Events and Treatment Retention in RA Patients Treated with Either Subcutaneous- or Intravenous-Golimumab in a Prospective, Observational Registry

Janssen supported clinical trial
1446: Cost-per-Responder Analysis of Sarilumab for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis (RA)
*Medical writing support provided by Prime, Knutsford, Cheshire, UK, funded by Sanofi and Regeneron Pharmaceuticals, Inc.*

1475: Heterogeneity in the Pattern of Use of JAK-inhibitors Between Countries Participating in an International Collaboration of Registers of Rheumatoid Arthritis Patients (the JAK-pot Study)
*The study is investigator initiated and supported by an unrestricted research grant from Pfizer. Funding source had no role in the design of this study, its execution, analyses, interpretation of the data, or decision to submit results.*

1477: Effect of Tocilizumab on HDL and LDL Characteristics in Patients with Rheumatoid Arthritis: Preliminary Results
*Study initiated by the researcher supported by Roche.*

1479: Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) &lt; 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA
*Bristol-Myers Squibb was involved in design, conduct, analysis, and reporting of the study.*

1480: Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study
*This study was sponsored by Bristol-Myers Squibb.*

1481: The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial
*The study was sponsored by Bristol-Myers Squibb.*

1482: Effect of ACPA IgM Serostatus on Efficacy Outcomes Following Treatment with Abatacept or Adalimumab: A Post Hoc Analysis of a Phase III Head-to-Head Trial
*Bristol-Myers Squibb was involved in design, conduct, analysis, and reporting of the study.*

1483: Impact of TNF Inhibitor Cycling with Adalimumab and Etanercept vs Switching to Tofacitinib
*This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Sarah Piggott, MChem, at CMC Connect, a division of McCann Health Medical Communications Ltd, Glasgow, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).*

1484: Comparison of Real-World Persistence of Subcutaneously Administered Biologic Disease-Modifying Antirheumatic Drug Therapies Among Patients with Rheumatoid Arthritis Switching from Another Biologic
*This study was funded by Genentech, Inc. Genentech, Inc. was involved in the design and execution of the study and in the reporting of the study results.*

1485: Predictors of Response to Etanercept-Methotrexate Treatment: Post-hoc Analysis of a Randomized, Open-label Study in Latin American Patients with Rheumatoid Arthritis
*This study was sponsored by Pfizer.*
1488: Real-Life Golimumab Persistence in Patients with Chronic Inflammatory Rheumatic Disease: Results of the GO PRACTICE Study
This study was designed and sponsored by MSD France in response to a demand by the French Healthcare Authorities

1489: Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study
This study was supported by grant from Chugai Pharmaceutical CO., LTD.

1491: Effect of Baricitinib on Functional Impairment in RA Patients with Moderate Disease Activity and an Inadequate Response to Conventional DMARDs
This study was sponsored by Eli Lilly and Company under licence from Incyte Corporation

1492: Real World Switching Patterns of Etanercept Original and Biosimilar in Germany
This study was sponsored by Pfizer.

1493: Tofacitinib in Patients with Rheumatoid Arthritis and Indicative of Depression And/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials
This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Sarah Piggott, MChem, at CMC Connect, a division of McCann Health Medical Communications Ltd, Glasgow, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

1494: Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany
This study was sponsored by MSD Sharp & Dohme GmbH, Germany

1496: Comparison of Different Remission Indices in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Data from Phase 3 Tofacitinib Studies
This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Sarah Piggott, MChem, at CMC Connect, a division of McCann Health Medical Communications Ltd, Glasgow, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

1497: Golimumab Improves Direct Costs of Healthcare Utilization and Indirect Costs Within Patients with RA, PsA, and as - Analysis of a Non-Interventional Study in Germany
This study was sponsored by MSD SHARP & DOHME GMBH, Haar, Germany

1498: Multi-Symptom Impact on the EQ5D Index in Bio-naive Active Psoriatic Arthritis Patients: An Analysis Through Week 24 of the GO-VIBRANT Study
The study sponsor was involved in the design, conduct, and reporting of the study.

1499: Clinical Characteristics and Treatment Profiles of Patients with Ankylosing Spondylitis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
This study was sponsored by Corrona, LLC. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie,
Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the abstract. Support for third-party writing assistance for this abstract, furnished by Kheng Bekdache, PhD, of Health Interactions, Inc, was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ.

1500: Real-World Use of Apremilast in Combination with Biologic Therapy in Patients with Psoriatic Arthritis: Findings from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
This study was sponsored by Corrona, LLC, which is supported through contracted subscriptions with multiple pharmaceutical companies. The abstract was a collaborative effort between Corrona and Celgene with financial support provided by Celgene.

1501: Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials
Study was funded by Novartis Pharma AG (Basel, Switzerland).

1502: Effect of Phosphodiesterase 4 Inhibition with Apremilast on Cardiometabolic Outcomes in Psoriatic Arthritis – Initial Results from the Immune Metabolic Associations in Psoriatic Arthritis (IMAPA) Study

The IMAPA study was funded by Celgene as an investigator-initiated trial. This study was conceived, designed, performed and analysed by investigators from the University of Glasgow. The study was sponsored by NHS Greater Glasgow and Clyde.

1503: The Impact of Time Since First Diagnosis on the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis
This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Siobhán Hoy, at CMC Connect, a division of McCann Health Medical Communications Ltd, Glasgow, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

1504: Secukinumab Provides Improvement in Nail Psoriasis and Inhibition of Radiographic Progression in Psoriatic Arthritis Patients with Nail Phenotype: 52-Week Results from a Phase III Study
This study was funded by Novartis Pharma AG, Basel, Switzerland.

1505: Ixekizumab Demonstrates Improvement Comparable to Adalimumab Across ACR Components in Biologic-Naïve Patients with Psoriatic Arthritis
This study is sponsored by Eli Lilly and Company.

1506: Impact of Apremilast on PsA Impact of Disease Core Components in Patients with a Limited Number of Active Joints: Results from a Real-World Study
This study was sponsored by Celgene Corporation.
1507: Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial
The ESTHER study was supported by an unrestricted research grant from Pfizer.

1508: Exposure-Response Analyses for Upadacitinib Efficacy and Safety in Ankylosing Spondylitis – Analyses of the SELECT-AXIS I Study
AbbVie sponsored the study; contributed to the design; participated in the collection, analysis, and interpretation of the data; and in writing, reviewing, and approval of the abstract.

1509: Improvement in the Signs and Symptoms of Psoriatic Arthritis with Ixekizumab Compared to Adalimumab in Patient Subgroups Defined by Baseline Disease Characteristics
Eli Lilly and Company funded this study. Lilly participated in the study design, data collection, and the analysis and reporting of study results.

1510: Guselkumab Was More Effective Than Secukinumab in Patients with Plaque Psoriasis and the Subset of Patients with Self-Reported Psoriatic Arthritis in a Randomized, Double-blind, Head-to-head Comparison Study over 1 Year
This study was sponsored by Janssen Research & Development, LLC.

1513: Comparative Effectiveness of Ustekinumab and TNF Inhibitors in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study
This study was sponsored by Janssen.

1514: Efficacy of Secukinumab in a US Patient Population with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies
Study sponsor: Novartis Pharmaceuticals Corporation. The authors thank Karen Chinchilla, PhD, of ArticulateScience LLC, Hamilton, NJ, for providing medical writing support/editorial support, which was funded by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

1515: A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions
Study sponsors: Novartis Pharmaceuticals Corporation. The authors thank Stephen A. Shinsky, PhD of ArticulateScience LLC, Hamilton, NJ for providing medical writing support and editorial support, which was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

1516: Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study
This study was designed and sponsored by MSD France in response to a demand by the French Health Authorities.

1517: Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?
This project was sponsored by a research grant from MSD. The sponsor had no role over the content of the abstract.

1518: Ixekizumab: 52-Week Efficacy and Safety in Radiographic Axial Spondyloarthritis Patients with Prior Inadequate Response/Intolerance to Tumor Necrosis Factor Inhibitors
This study was funded by Eli Lilly and Company. Lilly participated in the study design, data collection, and the analysis and reporting of study results.

1520: The Effect of Tofacitinib on Residual Pain in Patients with Psoriatic Arthritis
This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Mark Bennett, PhD, at CMC Connect, a division of McCann Health Medical Communications Ltd, Manchester, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

1521: Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials
This study was funded by Eli Lilly and Company. Lilly participated in the study design, data collection, and the analysis and reporting of study results.

1522: Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years
The study was sponsored by Novartis Pharma AG, Basel, Switzerland

1523: Persistence with Etanercept in Patients with Ankylosing Spondylitis or Psoriatic Arthritis in Germany: A Real-World Analysis
This analysis was sponsored by Pfizer.

1524: Long-Term Certolizumab Pegol Treatment of Axial Spondyloarthritis Is Associated with Rapid and Sustained Reduction of Active Inflammation and Minimal Structural Changes in the Spine: 4-Year MRI Results
This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.

1525: Certolizumab Pegol Improves Work and Household Productivity and Social Participation over 1 Year of Treatment in Patients with Non-Radiographic Axial Spondyloarthritis
This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.

1526: Certolizumab Pegol-Treated Patients with Non-Radiographic Axial Spondyloarthritis Demonstrate Improvements in Sleep Quality and Other Patient Reported Outcomes
This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.

1527: Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies
Novartis Pharmaceuticals Corporation. The authors thank Shelley Maria Lindley, PhD, of SciMentum Ltd, for providing medical writing support/editorial support, which was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, in accordance with Good Publication Practice guidelines (http://www.ismpp.org/gpp3).
**1528:** Ixekizumab Improves Fatigue, Pain, and Sleep up to 52 Weeks in Patients with Radiographic Axial Spondyloarthritis

*Eli Lilly and Company funded this study. Lilly participated in the study design, data collection, and the analysis and reporting of study results.*

**1530:** Impact of Baseline Body Mass Index on the Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis

*This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Sarah Piggott, MChem, at CMC CONNECT, a division of McCann Health Medical Communications Ltd, Glasgow, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).*

**1531:** Inadequate Response Within a Year of Biologic and Oral Synthetic DMARD Treatment Initiation Among Psoriatic Arthritis Patients in the USA Real-World Setting

*This study was funded by UCB Pharma.*

**1532:** Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials

*This study was funded by Eli Lilly and Company.*

**1533:** Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in Subjects Treated with Apremilast

*This study was sponsored by Celgene Corporation.*

**1534:** Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis

*The study was sponsored by Novartis Pharma AG. Academic advisors and Novartis personnel designed the study. Novartis conducted the data analyses. All authors had access to the data and vouch for the completeness and accuracy of the data and analyses.*

**1535:** Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases

*The study was funded by Pfizer. Pfizer played no part in the design, conduct or reporting of the study.*

**1536:** Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status

*This study was sponsored by Sun Pharmaceutical Industries, Inc.*

**1537:** Ixekizumab Is Effective in the Treatment of Radiographic Axial Spondyloarthritis Regardless of the Level of C-Reactive Protein or Magnetic Resonance Imaging Scores

*Funded by Eli Lilly and Company.*

**1539:** Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks

*This study is sponsored by Eli Lilly and Company.*

**1540:** Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis
resURFACE 1 and 2 were funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; editorial support was provided by Puneet Dang, PhD, of AlphaBioCom, LLC and funded by Sun Pharmaceutical Industries, Inc.

1541: Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—An Analysis from a Phase 2 Study
The study was funded by Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA.

1542: Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial
The study was funded by Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA.

1543: Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in a Phase 3 Study

1544: Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, funded the studies; Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, funded the analyses and medical writing support.

1545: Resolution of Enthesitis and Dactylitis Is Maintained over Two Years of Ixekizumab Treatment in Patients with Psoriatic Arthritis
Eli Lilly and Company funded this study. Lilly participated in the study design, data collection, and the analysis and reporting of study results.

1547: Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe
This study was sponsored by Novartis Pharma AG, Basel.

1549: ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Underlying Rheumatoid and Psoriatic Arthritis
These studies were performed and funded by Alpine Immune Sciences.

1550: Withdrawal of Ixekizumab Results in Loss of Efficacy in Multiple Clinical Domains in Patients with Psoriatic Arthritis Who Had Achieved Minimal Disease Activity: Results from the SPIRIT-P3 Study
Eli Lilly and Company funded this study. Lilly participated in the study design, data collection, and the analysis and reporting of study results.

1551: Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration
Amgen Inc., the sponsor of the SEAM-PsA trial, designed the trial in collaboration with academic investigators, oversaw data collection, performed the data analyses, and supported the development of this abstract. Data interpretation and writing of the abstract were performed by both the Amgen and non-Amgen authors.

1552: Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
This study was sponsored by Galapagos NV and co-funded by Galapagos NV and Gilead Sciences Inc.

**1553**: Achievement of Very Low Disease Activity and Remission Treatment Targets Is Associated with Reduced Radiographic Progression in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol
This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.

**1554**: A Novel MK2 Inhibitor for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
This study was sponsored by Celgene Corporation.

**1556**: Concomitant Treatment with Methotrexate Does Not Increase the Efficacy of Ustekinumab or TNF Inhibitors in Psoriatic Arthritis: Results from a Real-world, Multicenter Study
This study was sponsored by Janssen

**1557**: Ustekinumab and TNF Inhibitors Similarly Improve Patient-perceived Impact of Psoriatic Arthritis but Differentially Affect the Scale Subdomains: Results from a European Observational Cohort Study
This study was sponsored by Janssen

**1566**: Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States: Findings from a US Survey
This study was funded by Eli Lilly and Company.

**1580**: Early Treatment Failure with Apremilast Among Biologic-naïve Patients with Psoriatic Arthritis

Design, study conduct, and financial support for the study were provided by AbbVie; AbbVie participated in the interpretation of data, review, and approval of the abstract; all authors contributed to the development of the publication and maintained control over the final content.

**1581**: Long-Term Effectiveness and Safety of Infliximab and Golimumab in Ankylosing Spondylitis Patients from a Prospective Observational Registry
Janssen sponsored clinical trial.

**1587**: Long-Term Effectiveness and Safety of Infliximab, Golimumab and Ustekinumab in Psoriatic Arthritis Patients from a Prospective Observational Registry
Janssen funded clinical trial

**1602**: Predictors of Response, Adverse Events and Treatment Retention in Ankylosing Spondylitis Patients Treated with Golimumab in a Prospective, Observational Registry
Janssen supported clinical trial

**1611**: Ixekizumab Significantly Improves Self-reported Overall Health as Measured by Short-Form-36 in Patients with Active Non-radiographic Axial Spondyloarthritis: 16- and 52-Week Results of a Phase 3 Randomized Trial (COAST-X)
This study was supported by Eli Lilly and Company. Lilly participated in the study design, data collection, and the analysis and reporting of study results.

**1612**: Ixekizumab Improves Self-reported Overall Functioning and Health as Measured by the Assessment of SpondyloArthritis International Society Health Index in Patients with Active Radiographic Axial
Spondyloarthritis: 52-Week Results of Two Phase 3 Randomized Trials
This disclosure was funded by Eli Lilly and Company, which contributed to study design, data collection, data analysis, data interpretation, abstract preparation, and publication decisions.

1628: Primary 1-Year Data of Ixekizumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Patients with Radiographic Axial Spondyloarthritis Including Data in Patients Rerandomized from Adalimumab to Ixekizumab
This study was funded by Eli Lilly and Company. Lilly participated in the study design, data collection, and the analysis and reporting of study results.

1632: Ixekizumab Demonstrates Consistent Improvement up to Week 108 in Psoriatic Arthritis Across Individual ACR Components for Patients Naïve to Biologic DMARDs or with Previous Inadequate Response to TNF Inhibitors
This study was funded by Eli Lilly and Company. Lilly participated in the study design, data collection, and the analysis and reporting of study results.

1636: Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration
The EuroSpA Research Collaboration Network is financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, abstract preparation or decision to submit.

1643: Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results Through Week 52 from a Phase-3 Study
Janssen Research & Development, LLC supported this study.

1644: Impact of Peripheral Swollen and Tender Joints at Baseline on Response to Treatment with Secukinumab in Ankylosing Spondylitis
This study was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ. The authors thank Amos Race, PhD, of ArticulateScience LLC, Hamilton, NJ, USA for providing medical writing support/editorial support which was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

1653: Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study
The study was sponsored by Novartis Pharma AG, Basel, Switzerland

1655: Exposure–Response Modeling of an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, BMS-986165, for Pain Visual Analog Scale Score, in Patients with Psoriasis and Musculoskeletal Symptoms
This study was sponsored by Bristol-Myers Squibb. Professional medical writing assistance was provided by Linda Brown, MRPharmS, at Caudex, funded by Bristol-Myers Squibb.

1656: Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network
The EuroSpA Research Collaboration Network is financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, abstract preparation or decision to submit.

1665: HER2 as a Biomarker of Proliferative Lupus Nephritis in Children
This study was supported by the Lupus Foundation of America who had no role in design or analysis.

1666: Development of Comorbidity in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus
Role of the Study Sponsor(s): Bristol-Myers Squibb provided salary support for the first author.

1679: Impact of Diabetes on Risk of End Stage Renal Disease in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus
Role of the Study Sponsor(s): Bristol-Myers Squibb provided salary support for the first author.

1680: Oxidized Human Serum Albumin Is Increased in Systemic Lupus Erythematosus, but Not in Rheumatoid Arthritis
This research was conducted by the Nakatani Medical Instrumentation Technology Promotion Foundation.

1694: Persistency in Platelet C4d and Thrombosis Risk Score Associate with Thrombosis in Systemic Lupus Erythematosus
Exagen sponsored the study.

1697: Systemic Lupus Erythematosus Registries: Are the Measures Captured in the Real World Similar to Those in Clinical Trials?
Janssen Scientific Affairs, LLC supported this study.

1700: Disease Activity and Cognitive Function in Systemic Lupus Erythematosus
This study was partially funded by an unrestricted grant from Sanofi Genzyme.

1720: Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom
Funded by Boehringer Ingelheim.

1722: Evidence-based Consensus Statements for the Identification and Management of Interstitial Lung Disease in Systemic Sclerosis
This modified Delphi study was funded by Boehringer Ingelheim International GmbH, Germany. The sponsor had no influence on data generation and interpretation in this study.

1763: Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial
Funded by Boehringer Ingelheim.

1767: Efficacy and Safety of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use
The SENSCIS trial was funded by Boehringer Ingelheim.

1789: Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial
The SENSCIS trial was funded by Boehringer Ingelheim.

50
1800: Efficacy and Safety of Romilkimab in Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-Blind, Placebo-Controlled, 24-week, Proof of Concept Study
Sanofi (Study Sponsor) funded and conducted the study and analyzed the results reported in this abstract.

1801: Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
This study utilizes data from the nilotinib and belimumab trials in systemic sclerosis that were investigator-initiated studies supported by research grants from Novartis and GlaxoSmithKline, respectively.

1807: Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial
This study was sponsored by Boehringer Ingelheim International GmbH. Medical writing assistance was provided by John Carron of Nucleus Global, funded by Boehringer Ingelheim International GmbH.

1808: Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients - A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
This study was funded and data analysed by Vifor Pharma

1815: Maintenance Treatment in ANCA-Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems
Vifor Pharma funded and analysed this study

1818: Adaptive Study Design of a Randomized, Multicenter, 2-Part Phase 2 Trial of Replacement of Glucocorticoids by IFX-1, a C5a Inhibitor, in Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Trial conduct and reporting is funded by InflaRx GmbH, Jena, Germany

1821: Design of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of 2 Different Dose Regimens of IFX-1, a C5a Inhibitor, as an Add-On Therapy for Granulomatosis with Polyangiitis or Microscopic Polyangiitis
Trial conduct and reporting is funded by InflaRx GmbH, Jena, Germany.

1822: Pharmacogenetics and Pharmacodynamics of Response to Apremilast in a Phase 3 Clinical Study in Subjects with Active Behçet’s Disease
This study was sponsored by Celgene Corporation.

1825: Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 64 Weeks: Long-term Results from the Japanese Subgroup in a Phase III Study
This study was sponsored by Celgene Corporation.

1829: Clinical Characteristics and the Level Disease Activity of Behçet’s Disease in China: A Study Based on Smart System of Disease Management (SSDM)
Smart System of Disease Management (SSDM) was developed by Shanghai Gothic Internet Technology Co., Ltd.
1833: Pentoxifylline Gel for Oral Ulcers in Patients with Behçet’s Syndrome

1836: Mixed Cryoglobulin Immune Complex Proteomics: Analysis by Mass Spectroscopy
Results reported were funded by Gilead Sciences as an Investigator-initiated trial

1838: A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus
AstraZeneca funded this study with employees providing input into the design, implementation, and analysis of the results of the study.

1840: Biomarker Profiling Reveals Novel Mechanistic Insights into Ustekinumab Therapeutic Responses in Systemic Lupus Erythematosus
Janssen Research & Development, LLC supported this study.

1858: Defibrotide Inhibits Antiphospholipid Antibody-Mediated NET Release and Endothelial Cell Activation
Financial support for this pre-clinical pilot study was provided through a grant from Jazz Pharmaceuticals. Jazz Pharmaceuticals did not influence conduct or reporting of the study.

1859: Safety and Humoral Immunogenicity to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis (interim Analysis)
This study was supported by a grant from Pfizer to the Israeli Society of Rheumatology.

1863: Comparison of Infection-Related Hospitalization Risk and Cost in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis Treated with Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs
This study was sponsored by Bristol-Myers Squibb.

1872: Teprotumumab, a Novel Biologic for Active Thyroid Eye Disease
This study was funded by Horizon.

1874: Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation
This study was funded by Bristol-Myers Squibb. They did not have direct involvement in the conduct or reporting of the study but did review this abstract.

1875: Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials
This study was sponsored by Bristol-Myers Squibb. Professional medical writing assistance was provided by Katerina Kumpan, PhD, at Caudex, funded by Bristol-Myers Squibb.

1876: Continuing versus Withdrawing Ixekizumab in Patients with Psoriatic Arthritis Who Achieved Sustained Minimal Disease Activity: Results from the SPIRIT-P3 Study
This study was sponsored by Eli Lilly and Company.

1877: Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain
The study was funded by Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA.

1880: 6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with
Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network
The EuroSpA Research Collaboration Network is financially supported by Novartis. Novartis had no influence on the datacollection, statistical analyses, abstract preparation or decision to submit.

1886: Comparison of the Thrombosis Risk Score with Triple Positivity in SLE Thrombosis
Exagen performed the laboratory assays for this study.

1888: Ability of Inflammatory and Regulatory Soluble Mediators to Forecast Impending Clinical Disease Flare and Inform a Refined Lupus Flare Prediction Index in a Confirmatory Cohort of SLE Patients
Progentec Diagnostics, Inc. provided required matching funds for the Oklahoma Applied Research Support (OARS) grant funded by the Oklahoma Center for the Advancement of Science and Technology (OCAST). This grant provided salary support for Dr. Munroe, as well as materials required to carry out the study described in this abstract. Progentec provided approval for all aspects of the study, including study design, statistical analysis, and presentation of data performed by Dr. Munroe and co-authors.

1892: Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial
The SENSCIS trial was funded by Boehringer Ingelheim

1893: Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in a Randomized Clinical Trial
This study was funded by Genentech, Inc. Genentech, Inc. was involved in the design and execution of the study and in the reporting of the study results.

1895: Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial
F. Hoffmann-La Roche Ltd funded the study and analysis and was involved in writing the abstract.

1906: Risk Factors for Treatment Failure in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone versus Prednisone Alone
F. Hoffmann-La Roche Ltd funded the study and analysis and was involved in writing the abstract.

1907: Beta-2-Glycoprotein-1 IgA Antibodies Predict Coronary Plaque Burden, Progression and Moderate the Effect of Inflammation on Atherosclerosis in Rheumatoid Arthritis
The study sponsor only provided funds for the study. There was no involvement in study design, conduct, data collection, analysis or manuscript composition.

1914: Joint Tenderness and Ultrasound Inflammation in DMARD-naïve Early Rheumatoid Arthritis Patients
The ARCTIC trial received research grants from AbbVie, UCB Pharma, Pfizer Inc, MSD Norway, and Roche Norway. The funders of the study had no role in study design, data collection,
data analysis, data interpretation, or writing of the report.

1923: Improving Pneumococcal Vaccination Rates in High Risk Rheumatology Patients
Pfizer Pharmaceutical funded the projects to improve the vaccination rates.

This study was funded by Radius Health, Inc. Reused with permission from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). This abstract was accepted and previously presented at ISPOR 2019, in New Orleans, Louisiana. All rights reserved.

1931: Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial
Funding: Amgen, Astellas, and UCB Pharma

1937: Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study
Amgen Inc. sponsored this study

1973: Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids
This study was sponsored by Amgen Inc.

1974: Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial
This study was funded by Amgen Inc., Astellas, and UCB Pharma

1982: Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials
The study was sponsored by Eli Lilly and Company, under license from Incyte Corporation. The study sponsor designed the study and provided data analysis, laboratory and site-monitoring services, and writing support.

2011: Antibody Systems Targeting Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase Autoantigens Distinguish Rheumatoid Arthritis in Combination with Rheumatoid Factors
Exagen sponsored the study.

2012: Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA Calprotectin assays and funding for conducting them in the IMPROVED study was provided by Inova Diagnostics. Funders did not play a role in the design of the studies, in the collection or interpretation of the data, or in the preparation of the abstract.

2033: Association Between Rheumatoid Arthritis Treatment and the Risk of Death or Readmission After Major Surgery
This study was funded in part by Bristol-Myers Squibb. University of Pennsylvania and University of Alabama at Birmingham authors were responsible for the study design, analysis, writing of the abstract, and the decision to submit the abstract.

2051: Statin Exposure Moderates the Effects of Chronic Inflammation on Coronary Atherosclerosis Progression and Cardiovascular Events in Rheumatoid Arthritis
Pfizer was the study sponsor and funding was their only contribution. There was no involvement in study design, data collection, analysis or interpretation and manuscript writing.

2068: Biologics Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Non-calcified Coronary Plaque Progression and Stabilizing Vulnerable Plaques
The sponsor provided only study funding. The sponsor was not involved in the design, data capture, analysis, or manuscript preparation and did not provide any medication.

2070: Using Multi-modal Ultrasound to Assess Disease Activity Within the Salivary Glands of Patients with Primary Sjögren’s Syndrome Treated with Ixalumab (VAY736)
The clinical trial was designed, conducted and funded by Novartis Pharma AG

2092: Abatacept Reduces Serum CXCL13 and Disease-Relevant Immune Cell Phenotypes in a Double-Blind, Placebo-Controlled Primary Sjögren’s Syndrome Clinical Trial
Bristol-Myers Squibb was involved in design, conduct, analysis, and reporting of the study.

2097: Tuberculin Skin Test and Quantiferon®-TB Gold In-Tube Test for Latent Tuberculosis Before Biologic Treatments: Lower Agreement Rate in Spondyloarthropathies Compared to Rheumatoid Arthritis
DxTerity Diagnostics sponsored the study by providing financial support and testing of the patient samples.

2106: Disability and Health-Related Quality of Life Outcomes in Patients with Systemic or Polyarticular Juvenile Idiopathic Arthritis

Treated with Tocilizumab in Randomized Controlled Phase 3 Trials
F. Hoffmann-La Roche Ltd funded the study and analysis and was involved in writing the abstract

2116: Identification of Immunological Processes Associated with the Response to Abatacept in Rheumatoid Arthritis Using Longitudinal Blood RNA-seq Analysis
Role for the Study Sponsor(s): This work was sponsored by Brystol Myers Squibb. The sponsor had no involvement with the study design, interpretation or analysis of the data.

2145: Comprehensive Characterization of the Immune Infiltrate of Skin Biopsies from Cutaneous Lupus Erythematosus Patients Using Single Cell RNASeq
The research was funded by Biogen Inc.

2175: Mononuclear Leukocyte DNA Methylome Imprinting of Networked Signaling and Immunity Regulatory Pathways in Gout
The study received funding support for ARDEA/Astra-Zeneca/Ironwood in addition to NIH support. The commercial entities played no role in either the conduct or reporting of the study.

2180: Protective Effects of Intra-Articular Formulated Liraglutide in Osteoarthritis: Preclinical Studies

2187: The Rat Homolog to FX201, a Gene Therapy in Development for the Treatment of Osteoarthritis, Demonstrates Dose-Dependent Decreases in the Severity of Cartilage and Bone Lesions Following Anterior Cruciate Ligament Transection
Flexion provided funding for the study and a few employees of Flexion are serving as co-authors.
2188: Senescent Synoviocytes in Knee Osteoarthritis Correlate with Disease Biomarkers, Synovitis, and Knee Pain
Role of the Study Sponsor: The Phase 0 clinical study was designed, conducted, analyzed, and funded by Unity Biotechnology

2189: Novel Somatic Mutations Identified by Whole Genome Sequencing of Rheumatoid Arthritis (RA) Fibroblast-Like Synoviocytes (FLS)
Dr. Ainsworth analyzed the data under the direction of Drs. Firestein and Wang. The sponsor (AbbVie) played no role in data analysis or interpretation.

2192: A Composite IFN-Based Signature Is Associated with a Filgotinib-Specific Clinical Response in bDMARD-Experienced Rheumatoid Arthritis Patients
The sponsor (Gilead Sciences, Inc.,) participated in the FINCH-2 trial design, and was responsible for coordinating the collection, management and analysis of the data. The academic authors and sponsor coauthors were responsible for drafting, editing, and revising of the abstract.

2195: IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells
This study was sponsored by Gilead Sciences, Inc.

2196: Factors in Achieving Serum Uric Acid Target and the Occurrence of Gouty Arthritis: A Cross-sectional Study Based on Japanese Health Insurance Claim Data
This study was supported by Teijin Pharma Limited. The sponsor participated in the design of study, statistical analysis, and the interpretation of data.

2197: Body Mass Index and Systemic Corticosteroid Use as Indicators of Disease Burden and Their Influence on the Safety Profile of Certolizumab Pegol Across Indications
This study was funded by UCB Pharma. Editorial services provided by Costello Medical.

2198: Co-morbidities in Patients with OA and RA: Results from a Large US Rheumatic Disease Registry
This study was funded by Bristol-Myers Squibb.

2200: Efficacy and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adults with Pre-existing Potential Immune Mediated Diseases: A Pooled Post-hoc Analysis on Two Parallel Randomized Trials
GlaxoSmithKline Biologicals SA funded the development of the abstract.

2212: Features of Pneumocystis Jirovecii Pneumonia in Juvenile Idiopathic Inflammatory Myopathy
Childhood Arthritis and Rheumatology Research Alliance (CARRA) infrastructure, such as mailing lists, conference calls, and annual meeting space was used to sponsor this study.

2215: Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the
General Population: Incidence Rates Using Real-World Claims Data
This study was funded by Genentech, Inc.

2220: Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials
reSURFACE 1 and 2 were funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; editorial support was provided by Puneet Dang, PhD, of AlphaBioCom, LLC and funded by Sun Pharmaceutical Industries, Inc.

2244: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of the Anti-ADAMTS-5 Nanobody®, M6495, in Healthy Male Subjects: A Phase I, Placebo-Controlled, First-in-Human Study
This study is sponsored by Merck KGaA, Darmstadt, Germany. The study sponsor was involved in the study design, collection, analysis, and interpretation of data, and was involved in the decision to submit the abstract for publication.

2245: High Molecular Weight Intraarticular Hyaluronic Acid for the Treatment of Knee Osteoarthritis: A Network Meta-Analysis
This analysis was funded by Sanofi. Doctor Evidence was contracted to conduct this analysis.

2246: A Low Cartilage Formation & Repair Endotype Predicts Radiographic Progression in Symptomatic Knee Osteoarthritis Patients and Identifies Optimal Responders to a Potential OA Treatment
Several of the authors are employed by Nordic Bioscience, who supported the project through internal research budgets

2247: The Association of Plasma Fatty Acids Levels with Hand and Knee Osteoarthritis
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under Grant Agreement n° 115770, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. See www.imi.europa.eu and www.approachproject.eu. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. In addition, this work was supported by the Dutch Arthritis Foundation LLP-24. Furthermore, the NEO study is supported by the participating Departments, the Division and the Board of Directors of the Leiden University Medical Centre, and by the Leiden University, Research Profile Area ‘Vascular and Regenerative Medicine’.

2249: Reference Curves for the Knee Injury and Osteoarthritis Outcome Score in the Middle-aged Dutch Population
M Kloppenburg has received financial support from the Dutch Arthritis Foundation. All other authors have declared no conflicts of interest.

2256: Stabilization of Patellar Bone-Shape Correlates Significantly with Reduced Knee Pain Frequency After IA TPX-100 in Subjects with Bilateral Patellofemoral OA
The study was supported by OrthoTrophix, Inc. Study site and data management were provided by a contract research organization. Statistical
analyses were performed by an independent statistician.

**2257**: BMI Has Minimal Effect on Reduction of Symptoms in Patients with Osteoarthritis of the Knee Treated with Diclofenac 1% Gel
*This study was funded by GSK Consumer Healthcare*

**2260**: Machine Learning Defines the Relationship Between Structural Knee Osteoarthritis and Patient-Important Outcomes: An 8-year Study of 47,858 Knee MRIs from the Osteoarthritis Initiative (OAI)
*This study was funded by Flexion Therapeutics, Inc. (Burlington, MA, USA).*

**2269**: Clinically Relevant Improvements in Knee Osteoarthritis Pain with Diclofenac Sodium Gel 1%
*This study was funded by GSK Consumer Healthcare*

**2276**: Severe Acute Localized Reactions Following Intra-Articular Hyaluronic Acid Injections in Knee Osteoarthritis
*The study sponsor reviewed the study protocol, results, and draft of the abstract. They did not provide data nor did they analyze the data.*

**2281**: Magnetic Resonance Imaging of Knee Joint Protection Following an Intra-Articular Injection of Lipid-Based Dexamethasone Sodium Phosphate Sustained Release Formulation on Subjects with Knee Osteoarthritis
*The current clinical study reported was fully sponsored by Taiwan Liposome Company, Ltd.*

**2287**: Developing a Comprehensive Patient-Specific Disease Progression Prediction Model for Knee Osteoarthritis Using Machine/Deep Learning Methods

**2288**: Patients with Axial Spondyloarthritis Have Abnormal Microarchitecture Despite Normal Areal Bone Mineral Density and Trabecular Bone Score by DXA
*This study was performed with support of an investigator initiated grant from Novartis Pharmaceuticals.*

**2289**: What Are the Prescribing Trends and Satisfaction Levels with Analgesics for Osteoarthritis as Reported by US Rheumatologists, Orthopaedic Surgeons, and Primary Care Physicians?
*The study was funded by Eli Lilly & Co and Pfizer. RR and LV are employees and shareholders of Eli Lilly and Company. JCC, AGB, and LT are employees and shareholders of Pfizer Inc.*

**2307**: Polymyositis (PM) and Dermatomyositis (DM) Symptom Flares and Associated Impact from the Patient Perspective
Mallinckrodt Pharmaceuticals provided grant funding to The Myositis Association to support data collection and analysis.

**2350:** Symptoms and Impacts in Psoriatic Arthritis: Findings from Qualitative Patient Interviews

This study was sponsored by Bristol-Myers Squibb.

**2351:** Patient Factors Associated with Willingness to Change Rheumatoid Arthritis Medications

The study was funded by Pfizer, Inc under their Independent Grants for Learning and Change. The study sponsor was not involved in data collection, analysis and interpretation.

**2352:** Evaluation of Rheumatoid Arthritis Patients’ Preferences Using Discrete Choice Experiment

The study sponsor had NO role in the design of the study and did not have any role during its execution, analyses, interpretation of the data, or decision to submit results.

**2353:** Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis

The study was sponsored by Amgen Inc. The study sponsor participated in the design of the study, data interpretation and abstract writing.

**2354:** Patient and Clinical Characteristics Associated with Increased Willingness to Adopt RA Treatment After an Educational Intervention: An Analysis of the Confident Treatment Decisions for Living with Rheumatoid Arthritis (CONTROL-RA) Trial

The clinical trial was sponsored by Pfizer Independent Grants for Learning and Change.

The sponsor was not involved in data collection, analysis and interpretation.

**2364:** Patients’ Journeys Through Giant Cell Arteritis: A Qualitative Study

This study was funded by Genentech, Inc. Genentech, Inc., was involved in the design and execution of the study and in the reporting of the study results. Support for third-party writing assistance, furnished by Health Interactions, Inc, was provided by Genentech, Inc.

**2365:** Major Stressors in the Year Prior to Diagnosis Affects RA Characteristics at Presentation and 1 Year

CATCH was designed and implemented by the investigators and supported through unrestricted research grants from: Amgen and Pfizer Canada-Founding sponsors since January 2007; AbbVie since 2011; Medexus since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017 and Sandoz since 2019. Previously funded by Hoffmann-LaRoche and Janssen from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, and Sanofi Genzyme from 2016-2017.

**2366:** Impact of the Healthy Outcomes in Pregnancy with SLE Through Education of Providers (HOP-STEP) Program: A Mixed Methods Approach

This project is an independent medical education grant, funded by GlaxoSmithKline. The company did not contribute to the content of the www.LupusPregnancy.org nor the study.

**2367:** The Vasculitis Pregnancy Registry (V-PREG): Information from the First 3 Years

This work was conducted through the Vasculitis Patient-Powered Research Network and the Vasculitis Clinical Research Consortium with
financial support from PCORI (PPRN-1306-04758) and NIH (AR057319).

2369: Combined First-Trimester Serum BAFF and sFlt-1 Levels as an Early Biomarker of Spontaneous Abortion
This study was funded in part by an investigator-initiated-study award from GlaxoSmithKline. The sponsor played no role in the design, execution, or reporting of this study.

2372: Pregnancy Outcomes in Women Exposed to Golimumab

2373: Are Vitamin D Metabolite Levels at Time of Diagnosis Associated with Long-term Severe Cardiovascular Events in Early Diagnosed Rheumatoid Arthritis Patients, Aggressively Treated During 10 Year Follow Up? Post-hoc Analyses of Observational Data from the CIMESTRA Cohort
This work was supported by The Danish Rheumatism Association, who provided financial support to scientific personnel and vitamin D metabolite analyses [grant number R117-A2898-B553, R115-A2764-B553]. Silkeborg Region Hospital Research Fond and Research Foundation at Regional Hospital Midt provided financial support to vitamin D metabolite analyses. PhD fund at Region Southern Denmark [grant number 14/24417] and Faculty Scholarship of University of Southern Denmark provided financial support to scientific personnel. Novartis Healthcare Denmark A/S provided the ciclosporine (SandimmunNeoral) and placebo-ciclosporine and sponsored an independent GCP monitor. Nycomed provided methotrexate (Emthexate), folic acid (Apovit) and calcium/vitamin D (CaviD) supplementation. Schering-Plough provided betamethasone (Diprospan) and MSD provided alendronate (Fosamax). Pfizer Denmark provided an “unrestricted grant” to the project [grant number WS2583631]. The Oak Foundation provided a core grant [grant number OCAY-13-309] to Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital (Professor R. Christensen). The sponsors were not involved in the study design, data collection, analysis or interpretation, and had no influence on the publishing of data.

2375: Prognostic Markers for Preclinical Cardiovascular Disease in Rheumatoid Arthritis and Correlation with Disease Activity
AbbVie provided funding for the completion of the study.

2377: Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors and the Role of Auto-antibodies
This review was funded by Bristol-Myers Squibb. Doctor Evidence was contracted by Bristol-Myers Squibb to conduct this review.

2381: Epidemiology, Risk/Prognostic Factors, and Treatment Landscape in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Literature Review
This review was funded by Bristol-Myers Squibb. Doctor Evidence was contracted by Bristol-Myers Squibb to conduct this review.

2382: Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis
Myriad Genetics, Inc., the study sponsor, was involved in study design, data analysis, and data interpretation as encompassed by the author responsibilities of the authors from Crescendo Bioscience, Inc. and Myriad Genetics, Inc.

2385: Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the
Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis

Study funding and editorial support (Matt Lewis, Adelphi Communications Ltd) were provided by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. This abstract was previously presented at the 2019 European Congress of Rheumatology; 12–15 June; Madrid, Spain.

2386: Real-World Distribution of Anti-Cyclic Citrullinated Peptide Concentrations and Impact on Treatment Patterns of Patients with Rheumatoid Arthritis

This study was sponsored by Bristol-Myers Squibb.

2401: ACPA Testing and Resultant Treatment Patterns in Patients with Rheumatoid Arthritis: Findings from US Community Rheumatology Practices

This study was sponsored by Bristol-Myers Squibb.

2402: Replication of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis

This study was funded by Roche Nederland BV.

2403: Multi-center Analyses on 518 Cases with Rheumatoid Arthritis Developing Lymphoproliferative Disorders (RA-LPD): The Prognostic Factors and the Influence of Anti-rheumatic Drugs on LPD Development

This study was an investigator initiated study funded by Bristol Myers Squibb.

2407: Comparison of Healthcare Resource Utilization (HCRU) and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Switch to Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs

This study was sponsored by Bristol-Myers Squibb.

2408: The Effect of DMARDs on Cardiovascular Outcomes in Rheumatoid Arthritis: A Systematic Literature Review

This review was funded by Bristol-Myers Squibb. Doctor Evidence was contracted by Bristol-Myers Squibb to conduct this review.

2413: Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis

AbbVie Pharmaceuticals and Marriott Daughters Foundation funded this study via investigator-initiated grants. Data analyses were completed by investigators independent of AbbVie and Marriott Daughters Foundation.

2414: Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five-Year Results from a US-based Rheumatoid Arthritis Registry

This study was sponsored by Corrona, LLC. Corrona is supported through contracted subscriptions with multiple pharmaceutical companies. The abstract was a collaborative effort between Corrona and Pfizer Inc with financial support provided by Pfizer Inc. Medical writing support under the guidance of the
authors was provided by Anthony G. McCluskey, PhD at CMC Connect, a division of McCann Health Medical Communications Ltd, Glasgow, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

2415: Two Decades of Changes in RA Treatment and Disease Outcomes from the United States This study was funded by Bristol-Myers Squibb.

2416: Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports Study was sponsored by Eli Lilly and Company, under license from Incyte Corporation

2417: Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry This study was sponsored by Corrona, LLC and funded by Genentech, Inc. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analyses; all authors contributed to the interpretation of the results. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Inc., Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sun and UCB.

2419: Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA Bristol-Myers Squibb was involved in design, conduct, analysis, and reporting of the study.

2423: Relationships Between DAS28 Response and Clinical, Functional and Radiographic Outcomes in Year 2 of the COMET Study of Etanercept in Patients with Rheumatoid Arthritis This study was sponsored by Pfizer.

2441: Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study

2444: Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis This project was funded by an unrestricted grant of Gebro Pharma. Gebro did not take part in the study design, contests or recommendations. They provide funds for the meeting and methodologist.

2445: Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate Exagen

2446: Which Factors Influence Achievement of Treatment Satisfaction in Rheumatoid Arthritis? RABBIT is supported by a joint, unconditional grant from AbbVie, Amgen, Bristol-Myers Squibb, Celltrion, Hexal, Lilly, MSD Sharp & Dohme, Mylan, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis, and UCB.
2451: Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings
This study was initiated and sponsored by Astellas Pharma, Inc. Astellas was involved in the study design, data analysis, decision to publish, and preparation of the abstract.

2455: Hepatobiliary Events in >5000 Patients with Inflammatory Arthritis Treated with Biosimilar or Originator Etanercept in Routine Care, Results from the Danish Nationwide DANBIO Registry
This study was partly funded by Pfizer. The company had no influence on the decision to publish these data and had no access to the raw data.

2461: The Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis
AbbVie Inc. was the study sponsor, contributed to the study design, data collection, analysis and interpretation, and to writing, review, and approval of the final version. Medical writing support was funded by AbbVie and provided by John Ewbank, PhD, of 2 the Nth.

2467: A Prospective Analysis of Factors Impacting Medication Decision-Making in Patients with Rheumatoid Arthritis
Pfizer and Institute of Healthcare Improvement

2468: LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjögren’s Syndrome
Research sponsored by Novartis Pharma AG, Switzerland

2473: Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial
The ASAPIII trial is an investigator-initiated trial which was funded by an unrestricted grant from Bristol-Myers Squibb (BMS). Abatacept and placebo injections were provided by BMS free of charge. BMS had no role in the design of the study; collection, analysis, and interpretation of the data; or in publication of this study.

2474: Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren’s Syndrome (pSS) and RA Patients
Bristol-Myers Squibb. The study sponsor provided funding for the completion of the study and the development of the abstract.

2475: ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome
These studies were funded by Alpine Immune Sciences, Inc. (AIS), and the authors are employees and/or shareholders of AIS.

2476: A Phase 2a Study of MEDI5872 (AMG557), a Fully Human Anti-ICOS Ligand Monoclonal Antibody in Patients with Primary Sjögren’s Syndrome
This study was funded by AstraZeneca and Amgen

2477: An ex-vivo Assay to Evaluate the Efficacy of Different Treatments for Inhibiting B Lymphocytes Activation by Salivary Gland Epithelial Cells in Sjögren’s Syndrome
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806975. The JU receives support from the
In Primary Sjogren’s Syndrome (pSS) IL7 promotes the crosstalk between T lymphocytes and salivary gland epithelial cells and participates in IFN signature.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806975. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This study has been supported by funding from OSE Immunotherapeutics.

Rates of treated depression among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs, and corticosteroids in the US MarketScan database.

This study was sponsored by Celgene Corporation.

Impact of enthesitis on patient-reported outcomes and physician satisfaction with treatment: Data from a multinational patient and physician survey.

This study was funded by Eli Lilly and Company.

Clinical presentation and treatment of oligoarticular psoriatic arthritis in Canada: High frequency of smaller joint involvement.

This study was sponsored by Celgene Corporation.

Pain and anxiety are independent factors associated to sleep impairment in psoriatic arthritis: A multicentric study in 14 countries.

Pfizer only sponsored the study; it was not involved in the conduct and reporting of the study.

JAK-STAT signaling system in pannus formation of psoriatic arthritis: A therapeutic target.

This study was funded by Pfizer Inc.

Implementing the psoriatic arthritis disease activity score (PASDAS) in routine clinical practice: (im)possible?

AbbVie B.V. provided financial support for the project: implementation integral psoriatic arthritis information system. AbbVie B.V. had no influence on the data collection, statistical analysis, manuscript preparation, or decision to submit.
2512: Impact of Multidomain Disease Presentations on Overall Disease Burden Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

This study was sponsored by Corrona, LLC. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the abstract. Support for third-party writing assistance for this abstract, furnished by Kheng Bekdache, PhD, of Health Interactions, Inc, was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ.

2513: Prevalence of Disease Domain Presentations Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

This study was sponsored by Corrona, LLC. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis.

2514: Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA

This study was sponsored by Amgen, Inc.

2519: Burden of Disease at Treatment Initiation Among Biologic-Naive Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

This study was sponsored by Corrona, LLC, which is supported through contracted subscriptions with multiple pharmaceutical companies. The abstract was a collaborative effort between Corrona and Celgene with financial support provided by Celgene.

2520: Enthesitis Frequency and Treatment Patterns in Patients with Psoriatic Arthritis in Europe and Japan

Financial support for the study was provided by AbbVie. AbbVie participated in interpretation of data, review, and approval of the abstract. All authors contributed to development of the abstract and maintained control over final content.

2524: Unmet Treatment Needs in Patients with Psoriatic Arthritis

Financial support for the study was provided by AbbVie. AbbVie participated in interpretation of data, review, and approval of the abstract. All authors contributed to development of the
abstract and maintained control over final content.

2525: Opioid Use Surrounding Diagnosis of Inflammatory Arthritis
This study was funded by UCB Pharma.

2530: Differences in Clinical Characteristics, Quality of Life, Disability, and Work Productivity in Psoriatic Arthritis Patients by Gender: Findings from a Cross-sectional Survey in the US and Europe
The study sponsor was involved in the design, conduct, and reporting of the study.

2536: Predictors of DAPSA28 Remission at 6 Months in Bio-Naive Patients with Psoriatic Arthritis Starting a TNF Inhibitor in Clinical Practice—Results from the EuroSpA Collaboration
The EuroSpA Research Collaboration Network is financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, abstract preparation or decision to submit.

2537: Description and Prevalence of Spondyloarthritis in Unselected Patients with Psoriasis, Acute Anterior Uveitis, and Inflammatory Bowel Disease Presenting with Undiagnosed Back Pain
Abbvie provided unrestricted funding for this study. The sponsor had no role in the conduct or reporting of the study.

2542: Normalization of Inflammatory Gene Expression and Cellular Markers by Abatacept in the Skin Lesions of Psoriatic Arthritis Patients: A Biopsy Substudy of a Phase III Study
This was a BMS supported research collaboration.

2544: Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial
The study was sponsored by Novartis Pharma AG. Academic advisors and Novartis personnel designed the study. Novartis conducted the data analyses. All authors had access to the data and vouch for the completeness and accuracy of the data and analyses.

2546: The Impact of Psoriasis Severity on Outcomes Among Psoriatic Arthritis Patients Receiving Adalimumab
AbbVie was the study sponsor, contributed to study design, data collection, analysis and interpretation.

2547: Psoriasis Impact on Patient-Reported Outcomes in Psoriatic Arthritis in a Real-World Setting: Results from the APOPSIS Study

2548: What Influences Patients’ Opinion of Remission and Low Disease Activity in Psoriatic Arthritis? Principal Component Analysis of an International Study
The ReFlap study was funded through an unrestricted grant from Pfizer. They did not have input into data collection, analysis or interpretation.

2549: A Qualitative Study of Clinicians’ Perspectives on Barriers to Implementation of Treat to Target in Psoriatic Arthritis
This study was funded by unrestricted grants from Abbvie, Celgene, Lilly, Novartis and Pfizer. The funders had no input to the data collection, analysis or writing of the abstract.

2556: Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported
Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Jennifer Higginson, PhD at CMC Connect, a division of McCann Health Medical Communications Ltd, Glasgow, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

2558: Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Jennifer Higginson, PhD at CMC Connect, a division of McCann Health Medical Communications Ltd, Glasgow, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

2559: Cenerimod, a Potent, Selective and Orally Active Sphingosine 1-phosphate Receptor 1 Modulator, Reduced Blood Antibody-secreting Cells in Patients with SLE

2561: Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells
The study design, conduct, reporting, analysis, and preparation of the abstract was funded and performed by the Sponsor.

2562: 24-Month Outcomes Associated with Belimumab in Black/African-American Patients
with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States

2563: Within-Trial Cost Analysis of Flares from a Phase 3 Clinical Trial Evaluating Subcutaneous Belimumab for the Treatment of Systemic Lupus Erythematosus
GlaxoSmithKline (GSK) designed, conducted, and funded the study, contributed to the collection, analysis, and interpretation of the data, and supported the authors in the development of the abstract. All authors, including those employed by GSK, approved the content of the submitted abstract. GSK is committed to publicly disclosing the results of GSK-sponsored clinical research that evaluates GSK medicines and, as such, was involved in the decision and to submit the abstract for publication.

2565: Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome
Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer.

2571: Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States
Exagen Inc. sponsored the study

2572: Influential Factors in Promoting Treat-to-Target for Systemic Lupus Erythematosus via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)

Smart System of Disease Management (SSDM) APP is developed by Shanghai Gothic Internet Tevhnology Co., Ltd

2574: An Updated Meta-Analysis of the Efficacy and Safety of Mycophenolate Mofetil in the Induction Treatment of Chinese Patients with Lupus Nephritis

This study was sponsored and funded by Shanghai Roche Pharmaceuticals Ltd.

2576: Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE

GlaxoSmithKline (GSK) designed, conducted, and funded the study, contributed to the collection, analysis, and interpretation of the data, and supported the authors in the development of the abstract. All authors, including those employed by GSK, approved the content of the submitted abstract. GSK is committed to publicly disclosing the results of GSK-sponsored clinical research that evaluates GSK medicines and, as such, was involved in the decision to submit the abstract for publication.

2603: Clinician’s Simple Opinion of SLE Disease Progress: Used in a Clinical Trial

Role of Study Sponsor: This was a Phase 2 Clinical conducted by Xencor Inc. Dr. Deb Zack is an employee of Xencor. Dr. Joan Merrill was the Coordinating Investigator of the trial. Drs. Anca Askanase and Amit Saxena were site investigators in the trial. This abstract briefly references the major results of the trial, but primarily reports additional results from the database of clinical information from this trial.

2617: Safety Results of 50% Enrollment from a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Repository Corticotropin Injection in Patients with Systemic Lupus Erythematosus Despite Moderate-dose Corticosteroid Use

The study sponsor funded the study and editorial support (provided by MedLogix Communications, LLC).

2624: Abatacept Failed to Demonstrate Efficacy in an SLE Trial with Low Placebo Response Rates, Although Global Assessments Indicated Less Flare Severity

This investigator initiated study was conducted by funding from Bristol Myers Squibb (NCT02270957). BMS approved the study design, and the content of this abstract prior to submission. BMS was not involved in collection, analysis, and interpretation of data, nor in the abstract writing.

2637: Population Pharmacokinetics of Atacicept in Systemic Lupus Erythematosus (SLE) – an Analysis of Three Clinical Trials

EMD Serono, Inc., a business of Merck KGaA (Darmstadt, Germany) was involved in the study design of all studies, and the collection, analysis, and interpretation of the data, as well as the writing of the manuscript. EMD Serono (including EMD Serono authors) and all other authors approved the final version of the abstract and were involved in the final decision to submit the abstract to the congress.

2663: Histologic Findings from Paired Renal Biopsies and Clinical Outcomes: Results from a
Single Site in the Phase III Study of Abatacept in Patients with Proliferative LN
The study was sponsored by Bristol-Myers Squibb.

2665: Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated with the Selective Immunoproteasome Inhibitor, KZR-616
Kezar Life Sciences

2668: A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus
AstraZeneca funded this study with employees providing input into the design, implementation, and analysis of the results of the study.

2673: Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells
This study was funded by Mitsubishi Tanabe Pharma Corporation and co-authors include employees of Mitsubishi Tanabe Pharma Corporation.

2675: Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus - Meta-analyses of Observational Studies Published Between 1979 and 2018
This study was funded by the Lupus Foundation of America.

2689: PK/PD, Safety and Exploratory Efficacy of Subcutaneous Anifrolumab in SLE: A Phase-II Study in Interferon Type I High Patients with Active Skin Disease
This study was funded by AstraZeneca

2691: Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus
GlaxoSmithKline (GSK) designed, conducted, and funded the study, contributed to the collection, analysis, and interpretation of the data, and supported the authors in the development of the abstract. All authors, including those employed by GSK, approved the content of the submitted abstract. GSK is committed to publicly disclosing the results of GSK-sponsored clinical research that evaluates GSK medicines and, as such, was involved in the decision and to submit the abstract for publication.

2693: Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus
This study was sponsored by Janssen Research & Development, LLC

2698: Efficacy Analysis of Patients with Systemic Lupus Erythematosus Treated with Belimumab or Placebo Plus Standard Therapy in Phase 3 Trials by Baseline Levels of BLyS mRNA and Type 1 Interferon Inducible Gene Signature Status
GlaxoSmithKline (GSK) designed, conducted, and funded the study, contributed to the collection, analysis, and interpretation of the data, and supported the authors in the development of the abstract. All authors, including those employed by GSK, approved the content of the submitted abstract. GSK is committed to publicly disclosing the results of GSK-sponsored clinical research that evaluates GSK medicines and, as such, was involved in the decision and to submit the abstract for publication.

2701: Frequency of Juvenile Idiopathic Arthritis (JIA) Subgroups and JIA-associated Uveitis
Among JIA Patients Admitted to Referral Pediatric Rheumatology Clinics In Turkey: A Retrospective Study, JUPITER
The study sponsor Biogen funded and conducted the described study

2707: Clinical Evidence Supporting Therapeutic Potential of Activating the Immune Checkpoint Receptor BTLA in SLE
The Study Sponsor, Eli Lilly and Company, was responsible for the conduct and reporting of the studies reported in this post-hoc analysis. The primary efficacy and safety results of the studies have been previously published.

2708: Course of Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in the EUSTAR Database
Boehringer Ingelheim provided funding for the study. Medical writing support was provided by Ben Daniels, BSc(Hons), BA, on behalf of AMICULUM, Oxford, UK and was funded by Boehringer Ingelheim.

2710: Responsiveness to Change of the Modified Rodnan Skin Score in a Phase I/II Double-Blind Randomized Placebo-Controlled Trial
Pfizer Inc provided funding and Tofacitinib for the investigator-initiated trial.

2712: Comparison Between Long-Term and Conventional Rituximab-Maintenance Treatments: Results of a Placebo-Controlled Randomized Trial
MAINRITSAN2 trial was funded by a research grant and rituximab but was not involved in the study design and did not have access to the data.

2713: Urine Complement Ba Levels During Flares of Renal Disease in Patients with ANCA-Associated Vasculitis
This work was supported by a research grant from the Columbus Medical Research Foundation

2714: Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial
F. Hoffmann-La Roche Ltd funded the study and analysis and was involved in writing the abstract.

2724: Clinical Outcomes of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica Symptoms Treated with Tocilizumab in Routine Clinical Practice
This study was funded by Genentech, Inc. Genentech, Inc. was involved in the design and execution of the study and in the reporting of the study results.

2728: Pharmacokinetics and Pharmacodynamics of Tocilizumab in Combination with Prednisone Tapering in Patients with Giant Cell Arteritis: 3-Year Results from a Randomized Controlled Phase 3 Trial
F. Hoffmann-La Roche Ltd funded the study and analysis and was involved in writing the abstract.
2729: Presentation and Management of Giant Cell Arteritis in a Real-World Setting (Artemis Study)
The Study Sponsor participated to: redaction of the protocol, PAS and e-CRF and to analysis of the results.

2730: Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a US-based Electronic Health Records Database
This study was funded by Genentech, Inc.
Genentech, Inc., was involved in the design and execution of the study and in the reporting of the study results.

2738: GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis
Study was funded by Kiniksa Pharmaceuticals Ltd

2739: Treatment Patterns, Disease Burden and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
This study was funded by Genentech, Inc.
Genentech, Inc., was involved in the design and execution of the study and in the reporting of the study results. Support for third-party writing assistance, furnished by Health Interactions, Inc, was provided by Genentech, Inc.

2741: Increasing Use of Biologics over Time in the First Year After Diagnosis of Systemic JIA Among Patients Enrolled in the Childhood Arthritis &amp; Rheumatology Research Alliance (CARRA) Registry
Childhood Arthritis and Rheumatology Research Alliance (CARRA) is the study sponsor and Genentech provided financial support.

2742: Reasons for Initiation of Canakinumab of Patients with Systemic Juvenile Idiopathic Arthritis: A Retrospective Medical Chart Review from the United States
This study was funded by Novartis Pharmaceuticals Corporation, USA.

2756: Frequency of Juvenile Idiopathic Arthritis (JIA) Subgroups and JIA-associated Uveitis Among JIA Patients Admitted to Referral Pediatric Rheumatology Clinics In TurkEy: A Retrospective Study, JUPITER
This study was funded by AbbVie.

2760: Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study
Sponsored by Bristol-Myers Squibb.

2761: Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials
Sponsored by Bristol-Myers Squibb. Professional writing assistance was provided by Katerina Kumpan, PhD, at Caudex, funded by Bristol-Myers-Squibb.

2766: Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study
This study and medical writing support, provided by Joseph Hodgson, PhD, Adelphi Communications Ltd., were funded by Sanofi and Regeneron Pharmaceuticals, Inc. This abstract is submitted by the authors on behalf
of the DRI13925 Investigators. This abstract was accepted for presentation at the joint 2019 PReS-EULAR congress, 12–15 June, Madrid, Spain.

2771: Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry This study was sponsored by the Childhood Arthritis and Rheumatology Research Alliance (CARRA)<br>Financial support for this study was provided by Amgen Inc.

2773: Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis This study was sponsored by the Childhood Arthritis and Rheumatology Research Alliance (CARRA).<br>Financial support for this study analysis was provided by Amgen Inc.

2777: Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry Childhood Arthritis and Rheumatology Research Alliance

2779: Farber Disease (Acid Ceramidase Deficiency): The First Natural History Study of This Rare Disease Involving Symptoms Which Can Mimic JIA Enzyvant fully sponsored this study of the natural history of Farber disease as part of a clinical development program for a potential enzyme replacement therapy for patients with this rare condition.

2784: Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis

AbbVie funded the study, contributed to the design, collection, analysis, and interpretation of the data, and in the writing, review, and approval of the abstract. Medical writing support was provided by Michael Theisen, PhD, Maria Hovenden, PhD, and Janet Matsuura, PhD, of Complete Publication Solutions, LLC (North Wales, PA) and was funded by AbbVie.

2793: Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a Phase 3 Trial This study was supported by Eli Lilly and Company. Lilly participated in the study design, data collection, and analysis and reporting of study results.

2796: Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease Funding: Amgen, Astellas, and UCB Pharma.

2799: Differential Methylation of Peripheral Blood Adaptive Immune Cells in Individuals at High Risk for RA and with Early RA Compared with Controls Identifies Pathways Important in Transition to Arthritis The learners analyzed the data under the direction of Drs. Firestein and Wang. The sponsor played no role in data analysis or interpretation.

2818: Skin Disease Activity and Autoantibody Phenotype Are Major Determinants of Blood Interferon Signatures in Dermatomyositis The role of the sponsor, Pfizer, was to perform RNA sequencing.

2828: Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States
This work was supported by the Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network. AMP is a public-private partnership (AbbVie Inc., Arthritis Foundation, Bristol-Myers Squibb Company, Lupus Foundation of America, Lupus Research Alliance, Merck Sharp & Dohme Corp., National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Pfizer Inc., Rheumatology Research Foundation, Sanofi and Takeda Pharmaceuticals International, Inc.) created to develop new ways of identifying and validating promising biological targets for diagnostics and drug development.

2838: Toward a Liquid Biopsy for Lupus Nephritis: Urine Proteomic Analysis of SLE Identifies Inflammatory and Macrophage Signatures
This work was supported by the Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network. AMP is a public-private partnership (AbbVie Inc., Arthritis Foundation, Bristol-Myers Squibb Company, Lupus Foundation of America, Lupus Research Alliance, Merck Sharp & Dohme Corp., National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Pfizer Inc., Rheumatology Research Foundation, Sanofi and Takeda Pharmaceuticals International, Inc.) created to develop new ways of identifying and validating promising biological targets for diagnostics and drug development.

2841: Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis: Joint Safety Events in a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
This study was sponsored by Pfizer and Eli Lilly and Company, which were involved in the design, conduct, and/or analysis of the study.

2843: A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
The study was funded by Vizuri Health Sciences, LLC.

2846: Cartilage Thickness Modification with Sprifermin in Knee Osteoarthritis Patients Translates into Symptomatic Improvement over Placebo in Patients at Risk of Further Structural and Symptomatic Progression: Post-Hoc Analysis of a Phase II Trial
This study is sponsored by Merck KGaA, Darmstadt, Germany. The study sponsor was involved in the study design, collection, analysis, and interpretation of data, and was involved in the decision to submit the abstract for publication.<br><br>Biorex Science provided medical writing support, funded by Merck KGaA, Darmstadt, Germany.

2850: Patient Preferences for Attributes of Treatments for Chronic Pain Associated with Osteoarthritis Pain and Chronic Low Back Pain That Differentiate Nerve-Growth Factor Inhibitors, Nonsteroidal Anti-inflammatory Drugs, and Opioids in the United States: A Discrete-Choice Experiment

2851: A Phase I, Randomized, Double-blind, Placebo-controlled, Single Center, Single-dose
Escalation to Investigate the Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered DEN-181 in Adult Patients with ACPA+ Rheumatoid Arthritis on Stable Methotrexate

Janssen Biotech Inc sponsored the study, which was conducted by the spin-off company Dendright Pty Ltd. Data analyzed and reported by investigators from University of Queensland, Dendright and Janssen.

2853: Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier

Siemens Healthcare GmbH was responsible for project management and data analysis performed within this research.

2855: What Is Axial Spondyloarthritis? A Latent Class and Transition Analysis in the SPACE and DESIR Cohorts

The DESIR cohort has received an unrestricted grant from Pfizer allocated for the 10 years of the follow-up of the recruited patients.

2857: Higher Disease Activity Is Associated with More Spinal Radiographic Progression in Patients with Axial Spondyloarthritis Independently of Prior Exposure to TNF Inhibitors

FORCAST was supported by an unrestricted grant from Abbvie.

2864: Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients

Xencor, Inc. provided grant support for the research study described in this abstract, including clinical data, samples, and materials to complete the biomarker assays. Xencor provided approval of the following: analysis and presentation of data included in this abstract.

2874: Methotrexate Intolerance: A Qualitative Descriptive Study of the Adult Rheumatoid Arthritis Patients’ Perspectives

This abstract reports findings of a project funded by Pfizer. The overall aim of this three-phase project is to develop a scale to measure methotrexate intolerance in patients with rheumatoid arthritis. We are reporting findings from the first phase.

2875: The Association Between Omega-3 Supplementation and Disease Activity in a Rheumatoid Arthritis (RA) Observational Cohort

Our study sponsors did not play a role in the research for this abstract.

2876: Does Early Anterior Cruciate Ligament Reconstruction Prevent Further Meniscal Damage? Secondary Analysis of a Randomized Controlled Trial

The KANON study and this project received funding from The Swedish Research Council, Greta and Johan Kock Foundations, the Medical Faculty of Lund University, Region Skåne, Governmental funding of clinical research within the national health services (ALF), The Swedish Rheumatism Association, Thelma Zoegas Fund, The Stig & Ragna Gorthon Research Foundation, Swedish National Centre for Research in Sports, Crafoord Foundation, Tore Nilsson Research Fund, and Pfizer Global Research. Funding sources had no role in the design, collection, and interpretation of the data or the decision to submit for publication.

2877: Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis
This research study was conducted through financial support from Janssen Pharmaceuticals. Janssen representatives helped set the goals of the study but we had complete autonomy to conduct the research, analyze the data, and interpret our results according to our own academic standards.

2878: Implementing the BP Connect Systems-Based Blood Pressure Follow-Up Protocol with Community Rheumatology Clinic Teams
Funders played no role in the design, conduct, or interpretation of results.

2880: The First Phase 2a Proof-of-Concept Study of a Selective NLRP3 Inflammasome Inhibitor, Dapansutrile™ (OLT1177™), in Acute Gout
The phase II clinical trial was funded by Olatec Therapeutics LLC

2881: A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis
The study was sponsored by Idera Pharmaceuticals, Inc. (Cambridge, MA)

2882: Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects
Staff from the funding source Corbus Pharmaceuticals, Inc. contributed to the study design, monitored and collected the data from sites and central laboratories, generated statistical analyses of the data, and contributed to this abstract.

2887: Outcomes over the First 5 Years of Follow-up in a Very Early Rheumatoid Arthritis (RA) Cohort Recruited over 20 Years: Most of the Improvement Occurred Before the 2011 Implementation of Treat-to-Target (T2T)
Bristol-Myers Squibb (BMS) funded the current specific analyses of the data collected over 20 years by the peer-funded Early Undifferentiated PolyArthritis (EUPA) cohort. BMS did not have any control on the objectives and design of the EUPA cohort, the conduct of the EUPA cohort, the acquisition of the EUPA data, the reporting of the results or the submission of this abstract. While BMS supported the statistical analyzes reported here, BMS had no access to the individual data of patients nor on any information that could help identify individual patients.

2903: Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of the BRASS Registry
The BRASS registry is supported by Sanofi, Regeneron Pharmaceuticals, Inc., Bristol-Myers Squibb, and Crescendo Bioscience. Analyses presented here and medical writing support (Matt Lewis, Adelphi Communications Ltd) were funded by Sanofi and Regeneron Pharmaceuticals, Inc. This abstract was previously presented at the 2019 European Congress of Rheumatology; 12–15 June; Madrid, Spain.

2905: Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations
The ARCTIC trial received investigator initiated research grants from AbbVie, UCB Pharma, Pfizer Inc, MSD Norway, and Roche Norway. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
2907: The Pattern of Musculoskeletal Complaints in Patients with Suspected Psoriatic Arthritis and Their Correlation with Physical Examination and Ultrasound

The study was supported by unrestricted grants from UCB, Novartis and Celgene.

2909: Clinically Relevant Patient Clusters Identified by Machine Learning Tools in a Large Database from the Secukinumab Psoriatic Arthritis Clinical Development Program

The study was sponsored by Novartis Pharma AG, Basel, Switzerland

L03: Decision Tree Analysis to Identify Inflammatory Arthritis Patient Subgroups with Different Levels of Treatment Persistence with First-Line Subcutaneous TNF-alpha Inhibitors

This study was funded by Merck & Co., Inc., Kenilworth, NJ, USA. The sponsor was involved in the study design, analysis, interpretation of results, and abstract development.

L05: Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies

GlaxoSmithKline (GSK) designed, conducted, and funded the study, contributed to the collection, analysis, and interpretation of the data, and supported the authors in the development of the abstract. All authors, including those employed by GSK, approved the content of the submitted abstract. GSK is committed to publicly disclosing the results of GSK-sponsored clinical research that evaluates GSK medicines and, as such, was involved in the decision and to submit the abstract for publication.

L06: Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry

This study was sponsored by Corrona, LLC. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Pfizer Inc, Regeneron, Roche, Sun, UCB, and Valeant. This was a Corrona/Pfizer collaboration with Pfizer financial support. Medical writing support under the guidance of the authors was provided by Jennifer Stewart, PhD, MBA at CMC Connect, a division of McCann Health Medical Communications Inc, Radnor, PA, USA, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).

L09: Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs

The sponsor (Gilead Sciences, Inc.,) participated in the FINCH-2 trial design, and was responsible for coordinating the collection, management and analysis of the data. The academic authors and sponsor coauthors were responsible for drafting, editing, and revising of the abstract.

L11: Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controled Proof-Of-Concept Trial, of Golimumab Plus Methotrexate (MTX) versus MTX Monotherapy, in Improving Dactylitis, in MTX Naive Psoriatic Arthritis Patients

This investigator-initiated trial was supported by a research grant from MSD including golimumab and placebo supplies. MSD had no
influence on trial design, data analysis and publication.

**L12:** Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis
AbbVie Inc. funded the study (NCT02986373), contributed to its design, participated in data collection, analysis and interpretation

**L13:** Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti-Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
This study was funded by Sun Pharmaceutical Industries, Inc., Princeton, NJ.

**L14:** Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial
The study was sponsored by Novartis Pharma AG. Academic advisors and Novartis personnel designed the study. Novartis conducted the data analyses. All authors had access to the data and vouch for the completeness and accuracy of the data and analyses.

**L15:** Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
The abstract was sponsored by UCB Pharma

**L17:** Prospective Demonstration That Attainment of the Lupus Low Disease Activity State Is Associated with Improved Health Related Quality of Life
The Asia Pacific Lupus Collaboration received unrestricted project support grants from UCB, GlaxoSmithKline, Janssen, Bristol-Myers Squibb and AstraZeneca. These funders had no role in data collection, analysis, preparation, review or approval of the manuscript for publication.

**L18:** Cell-bound Complement Activation Products in Combination with Low Complement C3 or C4 Have Superior Diagnostic Performance in Systemic Lupus Erythematosus
Exagen funded the study.

**L19:** Cryopyrin-Associated Periodic Syndrome Treated with Canakinumab — Long-Term Follow-up Data Documents Sustained Safety and Remission
Novartis is the manufacturer of cabakinumab. Novartis Pharma GmbH is the Sponsor of this Long-term observational non-interventional study. Novartis is responsible for correct AE/SAE reporting and data integrity.

**L20:** Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial
Study was funded by Kiniksa Pharmaceuticals, Ltd.

**L21:** Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response
AbbVie, Inc was the study sponsor, contributed to study design, data collection, analysis, interpretation, writing, reviewing, and approval of the final version of the abstract.
L22: Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
This study was sponsored by Pfizer Inc. Medical writing support under the guidance of the authors was provided by Molly MacFadyen, MSc, and Claire Cairney, PhD at CMC Connect, a division of McCann Health Medical Communications Ltd., Glasgow, UK, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).